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ABSTRACT 
 
 
Protozoan parasites find a glucose rich environment when inhabiting the human 
host. As a consequence of this glucose rich environment, many parasites have evolved 
streamlined metabolisms that repress more complex pathways (such as the TCA cycle) in 
favor of high glycolytic activity, making glycolytic enzymes potential drug targets. The 
parasites also need to produce glycoprotein coats to shield themselves from the immune 
system, nucleotides for rapid proliferation, and reducing equivalents for redox 
homeostasis. The first enzyme of the glycolytic pathway, hexokinase (HK), is critical to 
the biosynthesis of all of these molecules, representing a here-to-fore underappreciated 
drug target. Herein I present evidence that HK is a promising target in the parasites 
Trypanosoma brucei, Leishmania major, and Plasmodium falciparum, and identify novel 
inhibitors of these HKs, which may have potential for drug development. T. brucei and 
Leishmania are neglected tropical diseases in dire need of new treatments, while P. 
falciparum is the world’s deadliest parasite, notorious for rapidly evolving drug 
resistance. In addition to my work on drug development, I have also investigated the 
unique biology of the T. brucei HK and its alternative cellular localization. This 
alternative cellular localization is driven by a unique peptide sequence found only in 
kinetoplastid parasites. Together, these findings demonstrate the fascinating novelty of 
parasite glucose metabolism, and its great potential as a drug target. 
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CHAPTER ONE 
 
LITERATURE REVIEW 
 
The African Trypanosome 
The Parasite and the Disease 
The African trypanosome, Trypanosoma brucei, is an extracellular protozoan 
parasite of the mammalian bloodstream, transmitted by the bite of a tsetse fly (Glossina 
spp.) vector. There are three subspecies of T. brucei, two of which infect humans and one 
of which does not. T.b. gambiense is anthroponotic (humans are its primary reservoir) 
and causes a chronic illness in humans that lasts for years. T.b. gambiense likely 
developed from sustained preying on humans by tsetse flies in central and West Africa 
(Steverding 2008). T.b. rhodesiense is a zoonotic parasite that causes acute human illness 
in south and east Africa, killing in months. T.b. gambiense infection is much more 
common than the zoonosis, accounting for ninety-eight percent of cases (Franco et al. 
2014). Together the two subspecies have an annual incidence of 300,000, with around 
10,000 new infections and 10,000 deaths, though the conditions in some endemic 
countries make accurate reporting difficult (Fevre et al. 2008).  
The third subspecies of parasite, T.b. brucei, causes a largely asymptomatic 
infection in wildlife and a wasting disease nagana (from n’gana, Zulu for powerless or 
useless) in livestock, costing 4.5 billion dollars in agricultural losses a year (Torr et al. 
2005). Humans are immune to T.b. brucei due to the presence of high-density 
lipoproteins called trypanosome lytic factors 1 and 2 (TLF1 and 2) that lyse the parasite. 
Both TLFs contain apolipoprotein L1 (ApoL1), which is trafficked to the lysosome after 
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uptake and forms an anion channel in the lysosome, leading to osmotic stress and lysis 
(Wheeler 2010). Both TLFs also contain haptoglobin related protein (Hpr), which binds 
hemoglobin that is recognized by T. brucei haptoglobin-hemoglobin receptor 
(TbHpHbR), thus increasing uptake of TLF (Wheeler 2010). There are few differences 
between the subspecies besides the TLF resistance mechanisms, allowing T.b. brucei to 
be used as a model in the laboratory.  
The two human infectious subspecies, T.b. gambiense and T.b. rhodesiense, have 
separately evolved TLF resistance mechanisms. T.b. rhodesiense possesses a serum 
resistance-associated (SRA) gene whose protein product binds and inactivates ApoL1 
(Oli et al. 2006). SRA is a pseudogene related to the variant surface glycoprotein (VSG) 
genes that T. brucei uses for antigenic variation. T.b. gambiense resistance is more 
complex. T.b. gambiense group 2 expresses less TbHpHbR and the receptor is less active 
due to a single amino acid mutation (Kieft et al. 2010). The gene TgsGP is essential for 
T.b. gambiense group 1 resistance (Capewell et al. 2013). TgsGP, like SRA, is a pseudo-
VSG gene, though its function is less clear, as it does not directly bind ApoL1, despite 
localizing to the flagellar pocket where TLF uptake occurs (Wheeler 2010).  
Human illness caused by African trypanosomes is known as human African 
trypanosomiasis (HAT), or sleeping sickness, due the parasite’s disruption of circadian 
rhythms once it invades the cerebral-spinal fluid. HAT has two major stages, the initial 
hemolymphatic stage and the later encephalitic stage. The hemolymphatic stage starts 
within a few weeks of being bitten by an infected fly as parasites begin to proliferate in 
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the blood and lymph, causing nonspecific, flu-like symptoms such as fever and headache 
(Kennedy 2004).  
The parasites reproduce quickly in the bloodstream and are adept at evading host 
immunity. Parasites are shielded from the host by a dense surface coat made of a single 
type of variant surface glycoprotein (VSG). Rapid turnover of the parasite plasma 
membrane slows the accumulation of host antibodies and complement, but the immune 
system does eventually recognize and clear the parasites. However, by this time a small 
subset of the parasite population will have changed which VSG gene is expressed, 
avoiding detection and destruction. With over 2,000 VSG genes (and the capacity to 
create new ones through gene rearrangement), this process can continue ad infinitum, and 
gives HAT a nearly one hundred percent mortality rate when untreated. Eventually the 
parasites breach the blood-brain barrier and colonize the cerebral-spinal fluid, where a 
wide range of neurological pathologies can be triggered, including the classic inversion 
of circadian rhythms (Kennedy 2004).  
The arsenal of medicines for HAT is severely limited, both in the number of drugs 
available and by the subspecies and disease stage each drug is effective against. Suramin 
or pentamidine are used against the hemolymphatic stage disease. Treatment of 
encephalitic stage is subspecies dependent, with eflornithine and nifurtimox used against 
T.b. gambiense and arsenical melarsoprol being the only option for T.b. rhodesiense. 
These treatments must be administered intravenously multiple times (difficult in many 
underdeveloped regions) and have severe side effects, particularly melarsoprol, which 
itself has a five percent mortality rate (Kennedy 2004). Additionally, diagnosis of the 
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disease is difficult, as the disease initially presents with nonspecific symptoms, and the 
wide range of symptoms in the later stage can be confused with other neurological 
disorders. Definitive diagnosis requires microscopic observation of blood samples (early 
stage) or lumbar puncture samples (late stage), making diagnosis challenging in rural and 
underdeveloped areas (Malvy and Chappuis 2011). Further frustrating diagnosis, T.b. 
gambiense and T.b. rhodesiense are morphologically indistinct and usually require 
genetic analysis (detection of SRA or TgsGP) in order to be identified. Despite the 
challenges presented by limited treatment options and the underdeveloped region the 
disease occurs in, elimination of T.b. gambiense has been deemed within reach (Franco et 
al. 2014), as the disease lacks significant animal reservoirs and the parasites have a low 
survival rate in the tsetse fly, with 0.1% of flies being competent for transmission (Malvy 
and Chappuis 2011). Elimination of T.b. rhodesiense is currently not feasible due the 
large number animal reservoirs (Franco et al. 2014). Further control of HAT will require 
improved screening and vector control measures, and the development of new 
therapeutics and diagnostic tools.  
 
History and Impact 
Phylogenies constructed from small subunit ribosomal RNA sequences suggest 
that trypanosomes have been in Africa as long as humans, and may have played a role in 
human evolution; humans are resistant to all trypanosomes with the exception T.b. 
gambiense and T.b. rhodesiense, which are believed to have evolved recently (Steverding 
2008). Indeed the majority of mammals in Sub-Saharan Africa tolerate trypanosome 
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infection well, with the exception of domestic animals, perhaps due to their recent 
evolution by artificial selection or perhaps their recent introduction into Africa from other 
regions (Steverding 2008). The first historical recordings of trypanosomaisis are found on 
Egyptian papyrus dating back to 2000 BC (Steverding 2008), which report a wasting 
disease in cattle called ushau, whose description matches that of nagana. Egyptian 
herdsmen mixed their stock with wild animals to create resistant lines (Steverding 2008). 
This practice was later abandoned after a change in the course of the Nile River by dam 
construction destroyed tsetse fly habitats in North Africa, limiting them to their current 
range in Sub-Saharan Africa (Steverding 2008). The first descriptions of sleeping 
sickness come from twelfth century Arabian travelers in Africa, such as the historian Ibn 
Khaldun, who wrote of an Emperor of Mali affected by “the sleeping illness” in 
fourteenth century (Steverding 2008). Arab and later European slave traders learned to 
avoid slaves with swollen lymph nodes of the neck, a classic sign of trypanosomasis 
(Steverding 2008). Despite this awareness and observation of sleeping sickness 
throughout history, investigation into the nature of the disease did not begin in earnest 
until the nineteenth century, when Europeans began to explore and colonize Africa.  
Three sleeping sickness epidemics have occurred in the twentieth century. The 
first two of these epidemics occurred at the beginning of the century as population 
movements (of humans and animal reservoirs) and environmental changes (ex. 
deforestation for cash crop production) brought on by European colonization disrupted 
the normally isolated foci of transmission where there was sustained contact between 
vectors, humans, and animal reservoirs (Malvy and Chappuis 2011). These epidemics 
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prompted colonial authorities to order initiatives to study and combat the disease 
(Steverding 2008). Sir David Bruce first identified trypanosomes in the blood of infected 
cattle, and established the tsetse fly as the disease vector (Bruce 1895). Later work 
identified the two human infective subspecies with T.b. gambiense identified by Dutton 
in 1902 and T.b. rhodesiense named by Stephens and Fantham in 1910. The first 
trypanocidal drugs were also developed at this time, most of which are still in use today. 
Suramin (originally Germanin) was developed by the German Bayer Company in 1917 
through the screening of synthetic dyes for trypanocidal activity (Steverding 2010). The 
compound was originally offered to Britain for the restoration of German colonies in 
Africa, but the British refused. In 1924 the French pharmacist Ernest Fourneau published 
the structure, which was later confirmed by Bayer (Steverding 2010). The diamidine drug 
pentamidine was developed in the thirties. Diamidines were originally investigated due to 
their hypoglycemic properties and the observation that trypanosomes consume large 
amounts of sugar, but it was later determined that the compounds themselves were 
trypanocidal (Steverding 2010). Arsenic based compounds were found to be effective as 
early as 1858 (Steverding 2010). The most effective and safe arsenicals developed were 
tryparsamide (1919) and melarsoprol (1949). Ernst Friedheim developed Melarsoprol by 
combining melarsen oxide with dimercaprol, which was used by the British during World 
War II to protect against lewisite, an arsenic gas based chemical weapon (Steverding 
2010). Tryparsamide use was discontinued in the sixties due to side effects, while 
melarsoprol remains in use today. Judicious screening and treatment campaigns by 
colonial authorities brought the disease largely under control by the 1960s, with less than 
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5,000 new infections per year (Steverding 2008). Tragically, lapses in these control 
programs during the transition of power in Africa from colonial authorities to 
independent governments led to a third epidemic that reached its peak in the 1990s 
(Franco et al. 2014). Better news came in the 1970s with the development of eflornithine, 
the first new sleeping sickness drug in decades. It is a designed inhibitor of ornithine 
decarboxylase (ODC) and was originally developed as an anti-cancer drug (Steverding 
2010). While a potent inhibitor of the human enzyme in vitro, the high turnover rate of 
human ODC precluded its use against cancer. Cyrus Bacchi showed that elfornithine was 
effective against a mouse model of sleeping sickness in 1980, and it was later found to be 
effective against encephalitic stage T.b. gambiense. The drug targets parasite ODC, and 
the difference in sensitivity is the consequence of a low turnover rate of parasite ODC 
(Steverding 2010). Elfornithine was introduced for human use in 1990 and helped bring 
the surging number of infections back down after their peak in 1997 (Frano et al. 2014). 
Elfornithine production may have been discontinued at the turn of the century if not for 
negotiations between the WHO and pharmaceutical companies due to the low 
profitability of production (Steverding 2008). Unfortunately, melarsoprol remains the 
only option against the encephalitic stage and T.b. rhodesiense, as it has a much higher 
ODC turnover rate than the other sub-species. 
 
The Life Cycle 
T. brucei has a complex life cycle, with multiple stages in both the insect and 
mammalian hosts (Figure 1.1). The bloodstream form trypomastigote is the proliferative 
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form in the mammalian host and the cause of pathology, dwelling in the bloodstream and 
capable of invading the cerebral-spinal fluid. This long slender form can be cultured in 
vitro in media. An unknown factor induces a subset of the trypomastigotes to develop 
into short stumpy forms, which have an arrested cell cycle and are pre-adapted for life in 
the tsetse fly. When taken up by a tsetse fly during a blood meal, short stumpy forms 
differentiate into procyclic form trypomastigotes in the tsetse midgut. These procyclic 
forms express tsetse specific coat proteins, called procyclins, over VSG and adapt their 
metabolism to the proline rich midgut environment. The most notable change is the 
development of an active mitochondrion and TCA cycle. This is the insect stage that can 
be cultured in the laboratory.  
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Figure 1.1 The Life Cycle of Trypanosoma brucei 
T. brucei has a complex life cycle (a), colonizing multiple tissues in the tsetse fly vector 
(b) and human host (c). Permission granted for use of the figure (Langousis and Hill 
2014). 
 
Procyclic forms exist in at least two stages, the early and late stages, which are 
distinct in their protein expression patterns and behavior (Imhof et al. 2014). Only the 
early stage procyclics express GPEET and show social motility in vitro when grown on 
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agar plates (Imhof et al. 2014). These early forms colonize the midgut and eventually 
penetrate the midgut wall and migrate though the fly’s alimentary canal, becoming late 
stage procyclics, which lack GPEET expression and social motility. The late stage 
procyclics reinvade the gut at the proventriculus and differentiate into proliferative 
epimastigotes, which infect the salivary glands, attaching to the epithelium. Meiosis and 
mating also occurs in the salivary glands, with compatible gametes recognizing each 
other via flagellar association and fusion (Peacock et al. 2014). After colonizing the 
salivary glands, the epimastigotes began to differentiate into metacyclic trypomastigotes, 
which are pre-adapted for the mammalian host and express VSGs required for successful 
bloodstream colonization. These infective cells are injected when the fly feeds, 
continuing the life cycle.  
 
Cell Structure 
T. brucei’s elegant, undulating form possesses many novel structures and features 
(Figure 1.2). A member of class Kinetoplastea, T. brucei’s mitochondrial DNA is 
packaged in a unique structure known as the kinetoplast. Mitochondrial, also called 
kinetoplast DNA (kDNA), plasmids form a chainmail-like structure that is attached to the 
flagellum through the basal body, with filaments that span the mitochondria membrane.  
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Figure 1.2 Cell Structure of Trypanosoma brucei 
Schematic showing the key organelles and structures of T. brucei. Permission granted for 
use of the figure (Matthews 2005). 
 
 During cell division the movement of the basal body helps ensure proper 
separation of mother and daughter kDNA (Langousis and Hill 2014). T. brucei possess a 
single, tubular mitochondria that branches out in the TCA cycle active procyclic form 
(Imhof et al. 2014). T. brucei also possesses a single flagellum which is attached to the 
cell except for the anterior tip, spiraling around cell in a corkscrew like pattern (hence the 
name Trypanosoma – from the Greek trypano- borer and soma - body). This 
configuration causes the beating of the flagella to elicit an undulating movement of the 
cell body for locomotion.  
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The flagellum is attached to the cell membrane and cytoskeleton through the flagellar 
attachment zone (FAZ). A crystalline paraflagellar rod (PFR) runs in parallel with the 
flagellar axoneme once it exits the cell. While its exact function is incompletely 
understood, the PFR is believed to have roles in structure and regulation, and is essential 
to motility (Langousis and Hill 2014). The flagellum is of central importance to the 
trypanosome, as motility is essential to virulence (Langousis and Hill 2014) and cell 
division (Ralston et al. 2009). Additionally, the site at which the flagella re-enters the cell 
body at the posterior end, the flagellar pocket, is the only site of macromolecule exchange 
with the environment, as the tight network of subpellicular microtubules of the 
cytoskeletion preclude exchange elsewhere (Langousis and Hill 2014). Endocytosis is 
essential to the parasite for nutrient acquisition and the pocket is the site of antibody 
clearance and VSG turnover. Finally, trypanosomes (and all other kinetoplasts) possess a 
unique metabolic organelle known as the glycosome.  
 
Glycosomes & Glycolysis 
Glycosomes are perioxisome-like organelles that house the enzymes catalyzing 
the first six or seven steps of the glycolytic pathway, in bloodstream forms and procyclic 
forms, respectively, due to life stage dependent express of cytoplasmic or glycosomal 
phosphoglycerate kinase (Blattner et al. 1998). In the bloodstream form, this 
compartmentalization results in a net balance of ATP and NADH generation and 
consumption, while the last three remaining steps generate two ATP in the cytoplasm 
(Figure 1.3).  
 13 
 
 
Figure 1.3 Compartmentalization of Glycolysis in Trypanosoma brucei 
Bloodstream form T. brucei compartmentalizes the first seven steps of glycolysis in 
modified peroxisomes known as glycosomes. The abbreviations used are as follows: 
ALD: aldolase; DHAP: dihydroxyacetone phosphate; 1,3BPGA: 1,3-
bisphosphoglycerate; ENO: enolase; F-6-P: fructose-6-phosphate; FBP: fructose 1,6-
bisphosphate; G-3-P: glyceraldehyde 3-phosphate; G-6-P: glucose-6-phosphate; GAPDH: 
glyceraldehyde-3-phosphate dehydrogenase; Glc: glucose; Gly-3-P: glycerol-3-
phosphate; GPDH: glycerol 3-phosphate dehydrogenase; Mito: mitochondrial enzymes; 
PEP: phosphoenolpyruvate; 2-PGA: 2- phosphoglycerate; 3-PGA: 3-phosphoglycerate; 
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PGI: glucose-6-phosphate isomerase; PGK: phosphoglycerate kinase; PGM: 
phosphoglycerate mutase; PFK: phosphofructokiase; PK: pyruvate kinase; PYR: 
pyruvate; TbHK: T. brucei hexokinase 1 and/or 2; TPI: triose-phosphate isomerase. 
Permission granted for use of the figure (Coley et al. 2011). 
 
Despite the modest ATP gain, the abundance of glucose in the bloodstream and 
the compartmentalization of the pathway allow modulated flux to meet the parasite’s 
energy needs. As the mitochondrion is inactive in the mammalian host, glycolysis and 
glycosomes are essential to BSF parasites, and are promising drug targets. Glycosomes 
undergo remodeling in procyclic cells and are active in this stage as well, but are not 
essential (Bauer et al. 2014, Parsons et al. 2001). Glycosomal proteins contain 
peroxisome-targeting sequences one or two (PTS1 and PTS2), which are a three amino 
acid sequence on the carboxy terminus (Gould et al. 1990) and an eleven amino acid 
sequence on the amino terminus (Tsukamoto et al. 1994), respectively. There is also a 
less common internal PTS (Peterson et al. 1997) of undefined sequence composition. The 
PTS1 and 2 sequences are recognized by the chaperones PEX5 (all PTS sequences) and 
PEX7 (PTS2), and translocated into the glycosome by the PEX14 complex (Figure 1.4), 
after which PEX5 and PEX7 are released back into the cytoplasm (Coley et al. 2011).  
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Figure 1.4 Glycosome Targeting in Trypanosoma brucei 
C-terminal peroxisome targeting sequences (PTS1) are recognized by the peroxin 5 
(PEX5) chaperone, which docks with the membrane bound peroxin 14 to import 
glycosome matrix proteins. Peroxin 7 recognizes the N-terminal PTS2, and also docks 
with PEX14. PEX7 may reach PEX14 via interaction with PEX5. Permission granted for 
use of the figure (Coley et al. 2011). 
 
Proper trafficking of glycosomal proteins is essential, as mislocalization has been 
shown to be lethal (Blattner et al.1998; Helfert et al. 2001). The two ATP consuming 
enzymes hexokinase (HK) and phosphofructokinase (PFK) are not regulated by feedback 
inhibition by their products, unlike the same enzymes from many other organisms, 
leading to the “turbo explosion” hypothesis that the lethality of the mis-localization of 
glycosomal proteins is due to unregulated depletion of cellular ATP (Haanstra et al. 
2008). The novelty and essentiality to the pathogenic stage of the parasite make 
glycolytic enzymes of particular interest.  
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The Hexokinases  
Hexokinase catalyzes the first step of glycolysis, the transfer of the γ phosphate of 
ATP to glucose, yielding ADP and glucose-6-phosphate. T. brucei possesses two 
hexokinases (TbHK1 and TbHK2). The proteins are 98% identical, with only ten 
different amino acids, seven of which are found at the C terminus. RNAi and gene 
knockout studies have shown that TbHK1 is essential to both procyclic and bloodstream 
form parasites, while TbHK2 is essential to bloodstream forms only (Albert et al. 2005 
and Chambers et al. 2008). The TbHKs have a number of novel features that distinguish 
them from orthologous enzymes. The enzymes are compartmentalized in the glycosome 
via a PTS2 sequence.  
Regulation is in part conferred by pH. Under acidic pH, an ADP binding site is 
revealed and ADP can be a potent inhibitor of the enzyme (Dodson et al. 2011). Notably, 
the metabolite glycerol-3-phosphate can protect TbHK1 from ADP inhibition at low pH 
(Dodson et al. 2011). Other means of regulation include regulated oligomerization. 
TbHKs form hexamers, while in most systems HKs are monomeric or dimeric (Chambers 
et al. 2008). It is unknown if TbHK1 and 2 form homo- or hetero-hexamers in vivo, but 
heterohexamers have higher catalytic activity in vitro (Chambers et al. 2008). In addition 
to their novelty compared to HKs for other organisms, the TbHKs have distinct properties 
from one another, remarkable considering their high identity. E. coli produced rTbHK1 
has robust catalytic activity in in vitro assays, while attempts to purify an active rTbHK2 
have been unsuccessful (Morris et al. 2006). Mutagenesis swapping of the last ten amino 
acids of the proteins reverses these properties, highlighting the importance of the C-
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terminal tail that harbors the majority of the amino acid differences. Curiously, 
heterohexamers of rTbHK2 with a catalytically dead rTbHK1 have activity, and have 
been used to demonstrate that TbHK2 is inhibited by pyrophosphate (Chambers et al. 
2008). At the genetic level, the two HK genes are in tandem on chromosome 10, and are 
part of the same polycistronically transcribed pre-messenger RNA. Differences in the 3’ 
untranslated region regulated differential expression of the TbHKs (Dodson, unpublished 
data). Recently Imof and colleagues showed that TbHK1 is upregulated in early stage 
procyclics, while TbHK2 is upregulated in late stage procyclics (Imhof et al. 2014). This 
is interesting given that TbHK2 double knockout procyclics have impaired social 
motility, which is only present in late stage procyclics (McAlpine, unpublished data).  
A TbHK2 specific antibody has also shown that TbHK2 has an alternative 
localization to the flagellum, challenging the dogma that extra-glycosomal TbHKs are 
toxic (Joice et al. 2012). Because of the lack of sufficiently specific tools, it is unclear if 
TbHK1 also has alternative localization. Published mitochondrial (Panigrahi et al. 2009) 
and flagellar proteomes (Oberholzer et al. 2011) suggest that both TbHKs have 
alternative localizations, but the sheer abundance of TbHK1 means that contamination 
cannot be ruled out. The essentiality of TbHK (making its inhibition lethal) and its low 
amino acid identity with host HKs (~28%,  allowing inhibitor selectivity over host 
enzyme ), make it a heretofore -underappreciated drug target. A recent high throughput 
screening (HTS) campaign identified TbHK1 specific inhibitory small molecules 
(Sharlow et al. 2010). Further work is needed to characterize the differences and 
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relationship between TbHK1 and 2, investigate their alternative localization, and further 
develop the leads found in the HTS. 
 
Leishmania 
The Parasite and the Disease 
Parasites in the genus Leishmania cause disease in an impressive spectrum of animals, 
including twenty-one species that affect humans. Kinetoplast relatives of T. brucei, these 
parasites are transmitted by sand flies of the genera Phlebotomus (Old World) and 
Lutzomyia (New World). The WHO estimates there are about 1.3 million cases of 
leishmaiasis annually, causing 20,000 – 30,000 deaths. Leishmania can be anthroponotic 
or zoonotic, depending on the species of parasite and vector. Leishmania is an 
intracellular parasite of host phagocytic immune cells, particularly macrophages. The 
parasite survives the harsh environment of the phagosome via a combination of 
adaptation to and modification of the compartment. Using immune cells as Trojan horses, 
Leishmania can affect a myriad of different tissues, including skin (cutaneous 
leishmaniasis), mucosal tissues (mucocutaneous leishmaniasis), and infections of internal 
organs (visceral leishmaniasis). The type of infection depends on the species and host 
factors, such as immune status. For example, AIDS patients are more likely to develop 
mucosal infections (Strazzulla et al. 2013). Old World (Eastern Hemisphere) Leishmania 
is usually cutaneous and/or visceral, and is mainly concentrated in Southern Europe, 
North Africa, the Middle East, India and Southeast Asia. New World (Western 
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Hemisphere) Leishmania is usually cutaneous and/or mucosal, and is mainly found in 
Mexico, Central America, and the Amazon basin.  
The presentation of symptoms depends on the form of the disease, but all forms of 
leishmaniasis begin as cutaneous infections, producing a single lesion around the location 
of the sand fly bite. These lesions usually heal, but some species can cause disperse 
cutaneous lesions throughout the body (L. amazonenesis) or have lesions metastasize to 
involve mucosal tissues (L. panamensis and L. braziliensis), or visceral tissues (L. 
donovani and L. infantum) (McGwire and Satoskar 2013).  
The pathogenesis of mucocutaneous leishmaniasis is currently not well 
characterized. In addition to the painful, disfiguring lesions, the destruction and 
inflammation of the upper respiratory tract can make breathing and eating difficult, and is 
conducive to secondary infections. Visceral infections mainly affect the spleen, liver, and 
bone marrow, causing pancytopenia and compromising immunity (McGwire and 
Satoskar 2013). Visceral Leishmania is also known as kala-azar, Hindi for “black fever,” 
a reference to the tendency of some strains of L. donovani in India to cause darkening of 
the skin.  
Relapses of Leishmania infections can occur after successful treatment. 
Reappearance of cutaneous infection at the periphery of healed lesions is known as 
leishmaniasis recidivans. A more severe form of relapse is Post-kala-azar dermal 
leishmaniasis (PKDL), characterized by diffuse dermal lesions after treatment of visceral 
infections. Both leishmaniasis recidivans and PKDL can occur after months or years of 
being asymptomatic.  
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The arsenal of drugs for leishmaniasis is diverse, but limited on a case-by-case 
basis depending on the species causing infection and the region where the infection 
occurred. Pentavalent antimonials are the most common treatment for leishmaniasis, but 
are problematic for a number of reasons: its mechanism of action is unknown, it is not 
orally bio-available (daily intravenous infusions can be difficult in the impoverished 
areas where Leishmania occurs), resistance is increasing (Kumar 2013), and there are 
many serious side effects, including cardiotoxicity (McGwire and Satoskar 2013).  
Amphotericin B is also commonly used for visceral leishmaniasis. Originally 
developed as an anti-fungal, amphotericin B binds ergosterol in the parasite membrane 
and forms a pore, disrupting membrane integrity and causing cytoplasmic leakage. While 
effective, amphotericin B requires long hospital stays and can cause serious renal 
complications; liposomal formulations of amphotericin B are much better tolerated, but 
higher cost often precludes its use.  
The aminoglycoside antibiotic paromomycin is sometimes used in combination 
with amphotericin B or alone, and works by inhibiting ribosome function by binding the 
16S subunit. Paromomycin has many common aminoglycoside side effects, including 
ototoxicity and nephrotoxicity (McGwire and Satoskar 2013). Pentamidine is another 
second line anti-leishmanial, but its mode of action is unknown and it has a myriad of 
toxic side effects. Originally intended as a cancer drug, Miltefosine is one of the few oral 
leishmaniasis drugs available, and is well tolerated. Unfortunately, miltefosine is not 
efficacious against all species, but importantly can treat visceral leishmanasis and PKDL 
(McGwire and Satoskar 2013). Cutaneous lesions can also be treated with heat or 
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cryotherapy. Full patient compliance for many these treatments is low, due to their 
toxicity, cost, and the amount of time required. Further, the number of cases of 
leishmaniasis recidivans and PKDL (5-10% of cases in India, 50% of Sudanese cases), 
show that the majority of these treatments do not provide a sterile cure (Zijlstra et al. 
2003). Thus, there is a growing need for novel Leishmania therapies.  
 
History and Impact 
Leishmaniasis has been present throughout human history, with one of the earliest 
reference to cutaneous lesions appearing on Assyrian tablets dating back over 2,500 years 
(Cox 2002). In the new world, Leishmania lesions have been found depicted in ancient 
sculptures and carvings. Physicians throughout history noted these sores, but the visceral 
disease was often confused with malaria, with similar symptoms such as fever and 
enlarged spleen. Leishmaniasis was first distinguished from malaria in 1824 in Jessore, 
India, where there was an outbreak of malaria-like fevers that failed to respond to 
quinine, and lacked the periodicity of malarial fevers (Cox 2002). Many thought visceral 
leishmaniasis to be a new virulent malaria species, until Leishman and Donovan 
independently demonstrated the parasite in the spleens of patients in 1900 (hence the 
name) (Leishman 1903 and Donovan 1903). The Phlebotomus sand fly vector remained 
elusive until 1921 (Sergent et al. 1921), and transmission through biting was not 
demonstrated until 1941 (Adler and Ber 1941). New World leishmaniasis was assumed to 
be identical, but in 1911 Vianna showed that the South American parasites were a 
different species (Vianna 1911) and in 1922 it was found that the New World vector was 
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a different genus, Lutzomyia. Vianna also discovered that the trivalent antimonial Tartar 
Emetic, originally used for sleeping sickness, could be used to treat cutaneous and 
mucocutaneous Leishmania, and pharmaceutical research in the 1940’s would result in 
the antimonials used today (Kumar 2013). Indeed, the entire pharmaceutical arsenal for 
leishmaniasis consists of drugs that did not have Leishmania as their original target: 
amphotericin B (fungi), paromomycin (bacteria, amoebas), pentamidine (T. brucei), and 
miltefosine (cancer).  
 
Life Cycle 
Leishmania parasites are extracellular parasites of their vectors, female sand flies 
of the genera Phlebotomus and Lutzomyia, and intracellular parasites of their vertebrate 
hosts, including humans (Figure 1.5). When an infected sand fly feeds, motile metacyclic 
promatigotes are injected into the host. Immune reaction to the bite results in the 
promatigotes being phagocytosed by macrophages or other phagocytic immunes cells. 
The parasite factors prevent phagosome maturation to avoid destruction and the 
promastigotes differentiate into proliferative, non-motile amastigotes that thrive within 
the phagosome, eventually lysing the cell, releasing infective amastigotes.  
When a sand fly feeds on an infected host and takes up infected host cells, 
amastigotes in macrophages sense the environmental change, triggering their 
transformation into procyclic promastigotes, which proliferate and colonize the sand fly 
midgut before becoming infective metacyclic promastigotes (Dostálová and Volf 2012). 
The details are unclear, but sexual reproduction appears to occur in the sand fly 
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(Rougeron et al. 2010). Leishmania was long thought to be clonal, but a population 
genetics study of L. braziliensis suggests sexual reproduction (Rougeron et al. 2009), and 
another study has used L. major strains with different selectable markers to show genetic 
exchange (Akopyants 2009). Promastigotes secrete a proteophosphoglycan gel known as 
promastigote secretory gel, which obstructs the sand fly digestive track, causing 
regurgitation during blood meals that promotes transmission, completing the life cycle 
(Rodgers 2012).  
 
 
Figure 1.5 The Life Cycle of Leishmania 
Leishmania is both an extra- and intra- cellular parasite as it cycles through mammalian 
hosts and sand fly vectors. Permission granted for use of the figure (Harhay et al. 2011). 
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Cell Structure 
As fellow kinetoplastids, Leishmania shares a number of structural similarities 
with T. brucei, including glycosomes, the flagellar pocket, single mitochondria, and their 
shared namesake the kinetoplast (Figure 1.6). In contrast to T. brucei, Leishmania has an 
external flagellum that is not associated with the cell membrane as a promastigote, and a 
severely shortened flagellum as amastigote. While the amastigote flagellum does not 
provide motility, it may still have an important role in sensing and cell-to-cell signaling 
(Gluenz et al. 2010). Additionally, Leishmania has an active mitochondrion in all life 
cycle stages.  
 
 
Figure 1.6 Cell Structure of Leishmania 
 25 
Diagram showing the structure of Leishmania promastigotes (left) and amastigotes 
(right). Permission granted for use of the figure (Besteiro et al. 2007). 
 
Hexokinases  
Leishmania genomes harbor two nearly identical hexokinases in tandem on 
chromosome 21 (89 to 99 percent amino acid identity depending on the species), which 
are similar to TbHK1 and 2, with 61 percent identity between L. major hexokinase 1 
(LmHK1) and TbHK1. Unlike T. brucei, Leishmania parasites also have a glucokinase, 
the role of which is unclear. The glucokinase has a low affinity for glucose (Km = 2.55 
mM), suggesting it may serve as a sensor of glucose levels or shunt excess glucose into 
alternative pathways such as the pentose phosphate pathway (PPP) (Caceres et al. 2007). 
Both hexokinases and the glucokinase contain PTSs, with HK1 and HK2 having an N-
terminal PTS2 and GK having a C-terminal PTS1. Despite having a PTS2, HK may 
moonlight as a hemoglobin receptor in the flagellar pocket (Krishnamurthy et al. 2004). 
Expression of a PTS2-truncated HK causes sugar toxicity in L. donovani, suggesting this 
alternative localization must be somehow regulated (Kumar et al. 2010).  
While Leishmania does not share T. brucei’s reliance on glycolysis – its 
mitochondria is active in all life stages- hexokinase may still be critical. Amino sugars 
may be the primary carbon source in the human pathogenic stages of the parasite, and 
metabolism of these compounds begins with phosphorylation by HK (Naderer et al. 
2010). Additionally, mannose metabolism is critical for virulence, due to the high 
mannose content of the parasite surface coat (Spath et al. 2000; McConville et al. 2002; 
 26 
Sacks et al. 2000) and the use of mannogen as the primary energy reserve (Ralton et al. 
2003).  HK contributes to the biosynthesis of both, either by producing G6P to be 
converted to mannose-6-P (M6P), or by phosphorylating mannose directly. Further 
studies will be needed to validate Leishmania HK as a potential drug target. 
 
Plasmodium 
The Parasite and the Disease 
Protozoan parasites in the genus Plasmodium cause the disease malaria in a 
variety of animals, including humans. Human malaria is caused by four species of 
protozoan parasites in the genus Plasmodium: falciparum, vivax, ovale, and malariae. 
Additionally, the primate parasite P. knowlesi can be zoonotically transmitted to humans. 
Of these species, P. falciparum is both the most common and the most virulent. P. vivax 
and ovale are also of concern, due to their ability to infect liver cells and remain 
quiescent, allowing recurrent infections to occur for years after the initial infection, 
making a sterile cure difficult. The parasites are transmitted by female mosquitoes in the 
genus Anopheles, which contains over a hundred species with global distribution.  
Malaria is a global health threat endangering over half the world’s population, 
with 3.3 billion people living in areas where transmission can occur. According to 
estimates by the WHO, there were more than 149 million cases of malaria in 2010, 
resulting in over half a million deaths, though these figures may be underestimations due 
to conditions in endemic countries (Snow et al. 2005). Over ninety percent of malaria 
related deaths occur in Africa, mostly in children under five. While malaria is not always 
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fatal, it also has significant effects on quality of life and economic development, reducing 
the gross domestic product of some endemic countries by over one percent.  
Malaria can cause a variety of symptoms, such as fever, fatigue, and vomiting. 
Complications such as renal failure (black water fever) and brain damage (cerebral 
malaria) can also occur with the more virulent P. falciparum.  
The blood stream stage accounts for the symptoms of malaria and thus is a target 
for anti-malarials for the treatment of malaria. The most common anti-malarials used fall 
under two main categories: quinine - derived compounds (such as chloroquinine) and 
artemisinins. Quinine based treatments, which prevent the parasite from sequestering 
toxic hemezoin that is produced by parasite metabolism of host erythrocyte hemoglobin, 
have been in use for decades and significant resistance has emerged, with several 
multidrug resistant strains identified (Dua et al. 2003). The more recently developed 
artemisinin based therapies have proven effective, but resistance has begun to emerge to 
these compounds as well (Amaratunga et al. 2012). Further, the anti-malarial mechanism 
of artemisinin is unknown, making the study of resistance or improvements to the drug 
difficult. Ever emerging resistance necessitates the development of new anti-malarials. 
 While mosquito nets and insecticides have reduced transmission, eradication 
remains elusive and is made difficult by the poor conditions and infrastructure in the third 
world countries where malaria is prevalent. Vaccine development has been frustrated by 
the intra-cellular nature of the parasite and its capacity for antigenic variation. Malaria 
eradication will require significant screening, vector control, and drug development and 
deployment campaigns in concert.  
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History and Impact 
Mosquitoes have always been a scourge of mankind, with mosquito borne illness 
accounting for more deaths in human history than any other cause. The majority of these 
deaths have come from malaria. The human infective species P. vivax, P. ovale, and P. 
malariae originated from monkey infective species in Africa that existed in regions into 
which humans migrated. Malaria was found across the majority of every continent other 
than Antarctica at the peak of its historical distribution. P. falciparum is a new comer, 
jumping from gorillas to humans as recently as 3,000 years ago, perhaps explaining its 
greater virulence compared to the older human infective species (Liu et al. 2010). 
References to illnesses resembling malaria are found worldwide; ancient Chinese medical 
books (~4,700 years ago), Hindu scriptures (~3,500 years ago), and Egyptian and 
Sumerian texts (~4,000 years ago) all mention diseases matching malaria (Cox 2010). 
Malaria reached Europe more recently; Greek and Roman texts only begin describing 
malaria less than 2,500 years ago, notably by Hippocrates in the third century BC. 
Interestingly the ancients’ notes of the fever’s periodicity and virulence allow us to infer 
the causative species, as each species has a characteristic periodicity: benign tertian 
(recurrence every two days, P. vivax and ovale), quartan (recurrence every three days, P. 
malariae), and malignant subtertian (recurrence every other day, P. falciparum). The 
association of malaria with mosquito dense areas was also made prior to germ theory and 
the elucidation of the disease’s means of transmission. High transmission rates in areas 
around marshes and swamps where mosquitos breed was attributed to the stagnant water 
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and foul air rather than the mosquitoes, hence the name malaria, from the Italian “mal 
aria,” or bad air. This knowledge led to some control of malaria transmission through the 
avoidance and drainage of swamps and marshes. Scientific inquiry into malaria’s cause 
and transmission began in the 1800’s, especially after the establishment of the germ 
theory by Pasteur and Koch. Charles Louis Alphonse Laveran, a French army medical 
officer working in Algeria, discovered the blood stage parasites in 1880 through careful 
observation of blood samples of infected and uninfected individuals, marking the first 
observation of a parasitic protozoan (Laveran 1881). Though it took him years to 
convince the scientific community at large, his efforts were eventually recognized with 
the 1907 Nobel Prize. Among the first to continue Laveran’s efforts was the Italian 
scientist Amico Bignami and his colleagues, who together with Briton Ronald Ross 
proved the transmission of the parasite by mosquitos in the late 1890’s (Ross 1898). The 
initial disappearance of the parasite when injected into the human host would remain a 
mystery until the discovery of the liver stage parasites by Henry Shortt and Cyril 
Garnham in 1947, and the cause of relapses of P. vivax and P. ovale would remain 
unresolved until the discovery of hypnozoites by Wojciech Krotoski in 1982 (Krotoski et 
al. 1982).  
The development of anti-malarials also began in the 1800’s. Chinchona bark 
powder was among the first remedies for malaria, and in 1820 its plasmodicidal 
components quinine and quinidine were identified (Cox 2010). Chemist William Henry 
Penkins attempted to make synthetic quinine in 1856 (a feat not accomplished until 
1944), and his resulting failure was mauve, the first synthetic dye (Cox 2010). This 
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sparked the German dye industry, and led to the screening of dyes for anti-microbial 
activity and staining (the same industry that would produce suramin, noted earlier). Paul 
Ehrlich discovered that methylene blue was an effective stain for the parasite in 1891, 
and in the 1920’s the German Bayer Company began testing methylene blue derivatives 
for plasmodicial activity (Cox 2010). Several of these compounds would become 
important drugs, particularly chloroquine and primaquine. Chloroquine, once a proper 
dosage regimen was developed, was a potent and cost effective anti-malarial prior to the 
emergence of resistant strains, and primaquine remains the only drug effective against P. 
vivax and P. ovale hypnozoites. The widespread use of the insecticide DDT and 
chloroquine after World War II eliminated malaria in much of the developed world and 
lowered incidence drastically in India, but concerns about DDT’s effect on the 
environment, resistant mosquitos, and the independent emergence of four different 
chloroquine resistant Plasmodium strains ended hopes of malaria eradication elsewhere in 
the 1960s. In 1971 Chinese scientists isolated the plasmodicidal component artemisinin 
from sweet wormwood, a traditional herbal remedy for malaria (Cox 2010). Artemisinin 
based treatments remain the most effective available today, but resistance has recently 
emerged in Southeast Asia (Amaratunga et al. 2012). Artemisinin resistance in Southeast 
Asia, the high preference for humans among African mosquitoes, and the lack of 
sufficient infrastructure and resources in many malaria endemic countries make the future 
of malaria control unclear, and makes the develop of new anti-malarials a priority.  
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Life Cycle 
Plasmodium infects multiple host and vector tissues to perpetuate its life cycle 
(Figure 1.7). When an infected mosquito takes a blood meal, sporozoites in the 
mosquito’s salivary gland enter the bloodstream of the human host. The sporozoites 
travel to the liver and infect liver cells as intracellular parasites, reproducing asexually to 
form multi-nucleated shizonts, which rupture and release up to 40,000 merozoites that 
then infect erythrocytes. P. vivax and ovale form hypnozoites during the liver stage, 
which can lie dormant and remerge later to re-establish active disease. Once inside the 
erythrocyte, immature trophozoites develop into shizonts that release merozoites, 
continuing the asexual erythrocytic cycle. The periodic emergence (rupturing shizonts) 
and disappearance (invading merozoites) of the parasites from the bloodstream causes 
episodic fever and chills as the immune system responds to the parasites. Trophozoites 
can alternatively develop into gametocytes that are infective to feeding mosquitoes. 
Sexual reproduction occurs in the mosquito midgut via fertilization of the female 
gametocyte by the flagellated male gametocyte, producing an ookinete. The mobile 
ookinete develops into an oocyst that bursts and releases sporozoites that travel to the 
salivary glands, completing the cycle. 
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Figure 1.7 The Life Cycle of Plasmodium 
Plasmodium cycles between mammalian hosts and mosquito vectors. Permission granted 
for use of the figure (Menard et al. 2013). 
 
Biology & Cell Structure 
Plasmodium, like most parasites in phylum Apicomplexa, possesses many unique 
cell structures to assist in host cell invasion. The phylum is named for the apical complex 
observed at the tip of invading Apicomplexan cells. The non-photosynthetic plastid 
organelle known as the apicoplast, was named for the only phylum in which it is found. 
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This unusual organelle has four membranes, the result of secondary endosymbiosis of a 
red alga by an Apicomplexan ancestor (Arisue and Hashimoto 2014). While the 
apicoplast has lost the ability to perform photosynthesis, it is essential to the parasite, 
performing vital functions such as lipid, isoprenoid, and heme biosynthesis. The 
apicoplast is housed within the apical complex, a collection of parasite specific structures 
that facilitate host cell invasion. The principal components of the complex are the 
rhoptries and micronemes, organelles which secret proteins essential to invasion. 
Invasion is achieved by forming a tight junction between host cell receptors and parasite 
ligands, followed by invagination of the host membrane to form the parasitophorous 
vacuole. Like T. brucei, Plasmodium’s mitochondria is dormant in the mammalian 
bloodstream, with the electron transport chain remaining active only to reduce 
ubiquinone (Tanaka et al. 2012) while an abridged TCA cycle produces acetyl-CoA 
(Olszewski et al. 2011). The specialized parasite digestive vacuole digests host 
hemoglobin for amino acids while sequestering toxic ferrous heme degradation 
byproducts as inert hemozoin. Overall the structure of Plasmodium is highly specialized 
for invasion and rapid proliferation.  
 
Hexokinase 
The blood stage of Plasmodium, like T. brucei, lacks a complete TCA cycle and 
depends on glycolysis for ATP production (Olszewski et al. 2011). Several lines of 
evidence support this dependence on glycolysis. Knockout studies of mitochondrial 
proteins (Tanaka et al. 2012) and radiolabeled carbon studies (using U-13C-glucose, U-
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13C-15N-aspartate and U-13C-15N-glutamine) (Olszewski et al. 2011) show that the 
mitochondria is not a significant contributor to cellular ATP levels, and Roth et al. found 
that the rate of glycolysis is increased up to 100-fold in infected erythrocytes (Roth et al. 
1988). Additionally, knockout studies show that the hexose transporter protein 
responsible for importing glucose for glycolysis is essential to the parasite (Slavic et al. 
2010), and inhibition of glycolysis with unmetabolizable glucose derivatives rapidly 
depletes parasite ATP (van Schalkwyk et al. 2008).  
The pentose phosphate pathway (PPP) is also critical to the parasite. The PPP is a 
sister pathway of glycolysis, as it also begins with glucose-6-phosphate produced by HK, 
and the two pathways share other intermediates, such as fructose-6-phosphate (Figure 
1.8). The pathway consists of oxidative and non-oxidative phases. The oxidative phase 
produces reducing equivalents in the form of NADPH. Both of Plasmodium’s antioxidant 
defense systems (one thioredoxin based and one glutathione based) are NADPH 
dependent, and the PPP is the main source of NADPH for the parasite (Preuss et al. 
2012). The non-oxidative phase produces ribose-6-phosphate, the precursor for de novo 
nucleotide synthesis. Indeed, the importance of the generation of lipid, isoprenoid, amino 
acid, and nucleotide precursors by glycolysis and the PPP may be underappreciated, as 
the parasite must synthesize large quantities of biomolecules to divide rapidly (Salcedo-
Sora et al. 2014). PPP activity is also increased in infected erythrocytes, up to 72 fold 
(Roth et al. 1986). The positioning of hexokinase at the top of these two essential 
pathways makes it an attractive drug target in Plasmodium. Furthermore, the Plasmodium 
genome contains only one copy of hexokinase, and this hexokinase has only ~26 percent 
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amino acid identity with human HKs (Preuss et al. 2012). Low identity with the host 
enzyme should allow selective inhibitors of the parasite enzyme to be identified. 
However, previous studies of Plasmodium falciparum hexokinase (PfHK) have been 
frustrated by an inability to produce soluble, active recombinant PfHK for in vitro studies 
(Olafsson et al. 1992). 
 
 
Figure 1.8 Overview of Glucose Metabolism in P. falciparum.  
The abbreviations used are as follows: 6PGD, 6-phosphogluconate dehydrogenase; 
DHAP, dihydroxyacetone phosphate; EPM, erythrocyte plasma membrane; GluPho, 
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glucose-6-phosphate dehydrogenase 6-phosphogluconolactonase; GLUT1, glucose 
transporter; HK, hexokinase; HT, hexose transporter; PPM, parasite plasma membrane; 
PVM, parasitophorous vacuole membrane; TPI, triosephosphate isomerase. Permission 
granted for use of the figure (Preuss 2012). 
 
Summary 
 In the following chapters I will present data showing the characterization of 
TbHK1 and the discovery and development of TbHK1 inhibitors that are lethal to T. 
brucei in culture. I also show that TbHK2’s alternative localization to flagellum is driven 
by a Kinetoplastid-specific peptide sequence in the N-terminus. Further, I explore the 
potential of HK as a drug target in the parasites P. falciparum and L. major, and screen 
the HKs from these parasites against a library of known TbHK1 inhibitors. Together, 
these studies will show the central role of HK in parasite metabolism, and the promise of 
HK inhibitors for new treatment options.  
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Abstract 
Glycolysis is essential to Trypanosoma brucei, the causative agent of African sleeping 
sickness, suggesting enzymes in the pathway could be targets for drug development. 
Ebselen (2-phenyl-1,2-benzisoselenazol-3(2H)-one, EbSe) was identified in a screen as a 
potent inhibitor of T. brucei hexokinase 1 (TbHK1), the first enzyme in the pathway. 
EbSe has a history of promiscuity as an enzyme inhibitor, inactivating proteins through 
seleno-sulfide conjugation with Cys residues. Indeed, dilution of TbHK1 and inhibitor 
following incubation did not temper inhibition suggesting conjugate formation. Using 
mass spectrometry to analyze EbSe-based modifications revealed that two Cys residues 
(C327 and C369) were oxidized after treatment. Site-directed mutagenesis of C327 led to 
enzyme inactivation indicating that C327 was essential for catalysis. C369 was not 
essential, suggesting that EbSe inhibition of TbHK1 was the consequence of modificaiton 
of C327 via thiol oxidation. Additionally, neither EbSe treatment nor mutation of the nine 
TbHK1 Cys residues appreciably altered enzyme quaternary structure.  
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Introduction  
Trypanosoma brucei is the causative agent of African sleeping sickness in 
humans and nagana in livestock, both of which have tremendous impact on the lives of 
people in sub-Saharan Africa (Brun et al., 2010). Bloodstream form (BSF) T. brucei, the 
life cycle stage that grows rapidly in the blood of the mammalian host, depends solely on 
glycolysis for ATP production. As a consequence, glycolytic enzymes from the parasite 
have been considered as potential targets for therapeutic design.  
The first enzyme activity in glycolysis, which transfers a phosphoryl group from 
ATP to glucose, is catalyzed by hexokinases (HK). T. brucei harbors two hexokinase 
genes, TbHK1 and TbHK2, and both gene products are essential to BSF parasite 
(Chambers et al., 2008a). The TbHKs, whether purified from parasites or heterologously 
expressed in E. coli, oligomerize into hexamers (Misset et al., 1986; Chamber et al., 
2008b). Due to the 98% identity of TbHK1 and TbHK2, the contribution of both to 
hexamer formation in vivo has remained elusive. Nonetheless, recombinant 
heterohexamers generated in vitro with known ratios of TbHK1 and TbHK2 have kinetic 
properties more similar to those reported for T. brucei-derived TbHK than recombinant 
TbHK homohexamers (Chambers et al., 2008b), suggesting that in the parasite oligomers 
are most likely heterohexamers. Notably, the composition of the heterohexamers in vivo 
is regulated in response to the nutritional environment in which the cells are cultured. The 
mechanisms behind this dynamic hexamerization, including the enzyme protein domains 
that participate in oligomerization, remain to be elucidated. 
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TbHK1 has previously been genetically and chemically validated as a potential 
target for therapeutic design. Further, the enzyme has been the subject of both structure-
based approaches and high throughput screening (HTS) campaigns to identify 
compounds with potential as leads in therapeutic development. The HTS campaign 
included the screening of 220,233 compounds for inhibitors of TbHK1 (Sharlow et al., 
2010a; Sharlow et al., 2010b). From this effort ten inhibitors, including six structurally 
related isobenzothiazolinone inhibitors have been identified. Ebselen (2-phenyl-1,2-
benzisoselenazol-3(2H)-one, EbSe, Fig. 1A), a selenium containing variant of 
isobenzothiazolinones, was the most potent TbHK1 inhibitor found in the HTS campaign, 
with an IC50 = 0.05 ± 0.03 µM. Notably, 2-phenyl-1,2-benzisothiazol-3(2H)-one (SID 
17387000, EbS, Fig. 2.1A), which differs from EbSe by replacement of the selenium 
atom with sulfur, was also identified in the HTS as a potent TbHK1 inhibitor (IC50 = 2.0 
± 0.5 µM).  
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Figure 2.1 Ebselen Inhibition of TbHK1 
 EbSe, a known Cys-reactive compound, inhibits TbHK1 activity. (A) Structures of 
ebselen (EbSe) and ebsulfur (EbS), SID 17387000. (B) EbS and EbSe inhibition are 
irreversible by dilution. TbHK1 (32 ng) was incubated with EbSe or EbS in the assay for 
15 minutes. Alternatively, inhibitor was incubated with enzyme prior to addition of other 
assay components, which yielded a 200-fold dilution of enzyme and inhibitor. (C) DTT 
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can block but not reverse TbHK1 inhibition by EbSe. TbHK1 (32 ng) was incubated with 
EbS or EbSe (hatched bars) followed by the addition of DTT (100 mM) prior to assay. 
Experiments were performed in triplicate and standard deviation is indicated. 
EbSe is known to form seleno-sulfide adducts with target protein Cys residues. 
For example, EbSe inhibited human indoleamine 2,3-dioxygenase (IDO) through 
covalent modification of multiple IDO Cys residues, causing a change in enzyme 
conformation and inactivation (Terentis et al., 2010). This EbSe-based oxidization of 
critical Cys residues can also result in the generation of inappropriate disulfide linkages 
(Sakurai et al., 2006). Here we explore the role Cys residues have in EbSe-based TbHK1 
inhibition. Through these efforts, we have found that EbSe oxidizes a single critical Cys 
residue, rather than promiscuously modifying Cys residues. Additionally, we have 
characterized the role of TbHK1 Cys residues in enzyme activity and the impact of their 
modification on oligomerization, finding that several of the Cys residues are essential for 
catalysis and can influence hexamerization. 
 
Materials and Methods 
Reagents  
Tris (2-carboxyethyl)phosphine (TCEP), glucose-6-phosphate dehydrogenase, β-
nicotinamide adenine dinucleotide (NAD+), adenosine triphosphate (ATP), and glucose 
were purchased from Sigma (St. Louis, MO). Dimethyl sulfoxide (DMSO) was 
purchased from Fisher Scientific (Pittsburgh, PA), while phosphoenol pyruvate (PEP), 2-
phenyl-1,2-benzisoselenazol-3(2H)-one (ebselen, EbSe, PubChem SID 856002) and 
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glucosamine were obtained from VWR International (West Chester, PA). 3-(N-
maleimidopropionyl)-biocytin was purchased from Cayman Chemical (Ann Arbor, MI). 
 
Recombinant Enzyme Purification and Assay Conditions. 
 Recombinant TbHK1 was purified as described from a culture of E. coli 
M15(pREP) harboring  pQE30 (Qiagen, Valencia, CA) with TbHK1 cloned in frame of a 
6-His tagging sequence (Morris et al., 2006). Briefly, a 10 mL bacterial culture was used 
to inoculate a 1 L culture which was grown to an OD of ~1 and then induced for 24 hr at 
room temperature with 250 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) and 
purified as described (Morris et al., 2006).  
TbHK1 Cys variants were generated using the parental pQE30 TbHK1 construct 
and a QuikChange II Site-Directed Mutagenesis Kit (Stratagene, LaJolla, CA). Primers 
used for the mutagenesis are listed in Supplementary Table 1 (Table S1) and generation 
of all variants was confirmed by sequencing. Protein expression and purification were 
performed as described above, with fractions from the purification probed by western 
blotting using an anti-RGS-His6 antibody (Qiagen, Valencia, CA) to identify those 
harboring the recombinant protein. All variants were at least 90% pure based on 
coomassie blue staining of proteins resolved by SDS-PAGE.  
HK assays were performed in triplicate as described using a coupled reaction to 
measure enzyme activity (Misset and Opperdoes, 1984; Morris et al., 2006). In short, the 
coupled assay uses glucose-6-phosphate dehydrogenase (G6PDH) to convert glucose-6-
phosphate (G6-P) generated by HK to 6-phosphogluconate with coincident reduction of 
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NADP to NADPH, which is monitored spectrophotometrically at 340 nm. Note that EbSe 
was found to be ineffective in a counterscreen for inhibition of G6PDH. Kinetic analyses 
were performed using KaleidaGraph 4.1 (Synergy Software, Reading, PA).  
 
Mass Spectrometry analysis of EbSe-treated TbHK1.  
Mass spectrometry was performed to map EbSe modification on TbHK1. First, 
solution samples were C4 zip tipped (Millipore) following the manufacturers protocol. 
The desalted protein was dried down and re-suspended in 100 ng of trypsin (Sigma, 
proteomics grade) and digested overnight at 37oC. The digested sample was then placed 
in an auto sampler vial for LC-MS/MS analysis. 
Enzymatically digested samples were analyzed via liquid chromatography (LC)-
electrospray ionization (ESI) -tandem mass spectrometry (MS/MS) on an Orbitrap Elite 
mass spectrometer (Thermo) coupled to a Dionex 3000 nano LC system. A 20 cm 75 
micron C-18 reversed phase LC column (packed in house, with Waters ODS C18) was 
utilized with a 200 nL/min flow rate and a 120 min gradient from 2% acetonitrile, 0.2% 
formic acid to 50% acetonitrile, 0.2% formic acid. MS data were acquired in a data-
dependent strategy selecting the fragmentation events based on the precursor abundance 
in the survey scan (400–1700 Th). The resolution of the survey scan was 60,000 at m/z 
400 Th with a target value of 1e6 ions and 1 microscan. Low resolution CID MS/MS 
spectra were acquired on the top 20 ions, with a target value of 1000 ions in normal CID 
scan mode. MS/MS acquisition in the linear ion trap was partially carried out in parallel 
to the survey scan in the Orbitrap analyzer by using the preview mode (first 192 ms of the 
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MS transient). The maximum injection time for MS/MS was 100 ms. Dynamic exclusion 
was 120 s and early expiration was enabled. The isolation window for MS/MS 
fragmentation was set to 2 Th. 
MS/MS data was searched against a custom database containing the users 
provided sequence using the searching algorithm node Sequest HT in Proteome 
Discoverer 1.4 (Thermo). Variable modifications of oxidation on methionine and Cys, di-
oxidation and tri-oxidation of Cys, the addition of EbSe to cysteine, the substitution of S 
with Se, and the conversion of Cys to dehydro-Ala were all considered. 
 
Native Gel Analysis and Negative Stain Transmission Electron Microscopy.  
For native gels, protein samples were diluted in native gel loading buffer (10% 
(v/v) glycerol, 2.7 mM Tris-HCL, pH 6.8, 0.1% bromphenol blue) and resolved on a 4% 
polyacrylamide gel (4% bis acrylamide, 375 mM Tris-Cl, pH 8.8, 0.05% (v/v) TEMED, 
and 0.05% ammonium persulfate) using a Tris/glycine buffer (2.7 mM Tris-HCl and 192 
mM glycine, pH 6.9) (Chambers et al., 2008b). Proteins were detected by silver staining. 
 For electron microscopy, samples were prepared by placing a drop of protein in 
solution on a formvar coated copper TEM grid held in anti-capillary forceps. The protein 
was allowed to settle to the grid surface for 60 seconds and excess liquid wicked away 
with a filter paper. The grids were then stained with a drop of aqueous 2% uranyl acetate 
for 30 seconds after which the excess stain was wicked away. Images of the negatively 
stained protein particles were collected using a JEOL JEM 1200 EX transmission 
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electron microscopy equipped with a Gatan Orius 830 camera. The images were prepared 
for publication using Adobe Photoshop. 
 
3-(N-Maleimidopropionyl)-biocytin (MPB) Assays.  
TbHK1 and variants (equal amounts as determined by coomassie staining of an 
SDS-PAGE gel) were incubated (30 min, RT) with MPB (50 µM) in buffer (20 mM 
Na2HPO4, 5 mM glucose, 0.4 M (NH4)SO4), resolved by 4% native gel electrophoresis, 
and monomers analyzed following transfer to nitrocellulose by western blotting using an 
anti-biotin antibody (1:10,000; Cell Signaling Technology Danvers, MA). Relative 
darkness was quantitated using ImageJ software. To score the consequences of inhibitor 
on MPB labeling, TbHK1 was incubated with increasing concentrations of inhibitor (15 
min, RT) followed by addition of MPB (50 mM), and the mixture incubated for an 
additional 30 min at RT. 
 
RESULTS 
In two independent screens for TbHK1 inhibitors, we identified EbSe (2-phenyl-
1,2-benzisoselenazol-3(2H)-one) as a potent TbHK1 inhibitor. In the first, a LOPAC 
screen, EbSe inhibited TbHK1 88.1 ± 0.6% at 10 mM. Also, EbSe and five other 
structurally related isobenzothiazolinones were identified as TbHK1 inhibitors during a 
high throughput screen (HTS) of 220,233 small molecules (Sharlow et al., 2010b). While 
EbSe was the most potent inhibitor identified (IC50 = 0.05 ± 0.03 µM), the finding that it 
can form covalent seleno-sulifide conjugates with Cys residues or act as a Cys oxidant 
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suggested that it was not an ideal lead for further development. Supporting this 
supposition, EbSe had been identified as an inhibitor of a number of different enzymes in 
multiple validated HTS campaigns, possibly because of its Cys-reactive nature (Sharlow 
et al., 2010b).  
Other Cys reactive TbHK1 inhibitors have also been identified. For example, the 
thiol-reactive reagent 4-chloromercuribenzoic acid was identified in the LOPAC screen 
as a potent inhibitor of TbHK1 (84.7 ± 0.4% inhibition at 10 mM) (Sharlow et al., 
2010b). Additionally, the irreversible disulfide-reactive reagent tris (2-
carboxyethyl)phosphine (TCEP) inhibited TbHK1 (IC50 = 6.6 ± 0.4 mM), supporting the 
possibility that a Cys residue (or multiple Cys residues) is important for catalysis.  
 
Neither dilution, DTT, nor excess Mg2+ can reverse EbSe inhibition of TbHK1.  
  Six isobenzothiazolinones were identified in the HTS as potent inhibitors of 
TbHK1, including EbS (SID 17387000), which is a structural analog of EbSe that harbors 
a S atom in place of the Se found in EbSe (Figure 2.1A). Inhibition by this compound or 
by EbSe was not reversible by 200-fold dilution of the inhibitor after pre-incubation with 
enzyme, suggesting a covalent modification of TbHK1 (Fig. 2.1B). Because EbSe 
inhibition of human IDO had been reported to be reversible by inclusion of the reducing 
reagent dithiothreitol (DTT) (Terentis et al., 2010), we assessed the consequences of this 
reagent on both EbS and EbSe inhibition (Fig. 2.1C). Alone, DTT (100 mM) had little 
impact on enzyme activity. Addition of DTT after either EbS or EbSe incubation only 
modestly rescued enzyme activity. While pre-incubation of TbHK1 with DTT prevented 
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EbSe inhibition (data not shown), it is likely this occurred as a result of DTT interacting 
directly with EbSe to block association of the small molecule with the enzyme. A report 
describing the formation of DTT/EbSe adducts supports this possibility (Borges et al., 
2005). Last, EbSe could be inhibitory to TbHK1 as a result of causing inappropriate 
coordination of the essential Mg2+ cofactor. Addition of excess Mg2+ did not relieve EbSe 
inhibition, even at ~15-fold higher concentrations than are used in the standard reaction 
(data not shown). 
 
MPB as a probe for exposed Cys interactions with inhibitors.  
To further explore the role of surface-exposed Cys residues in inhibitor binding, 
the Cys modifying reagent 3-(N-maleimidopropionyl)-biocytin (MPB) was used to 
modify surface-exposed Cys residues (Bayer et al., 1985). At concentrations up to 50 
mM, MPB did not impact enzyme activity; however, pre-incubation with MPB did not 
appreciably alter EbSe inhibition, suggesting that the residues accessible to MPB were 
not involved in the enzyme inhibition or that EbSe could compete with the MPB 
modification or interact with free MPB.  
 
Mass Spectrometry to identify covalent modifications of TbHK1.  
Because the MPB experiments did not clarify the role of Cys residues in EbSe 
inhibition, we pursued scoring the direct consequences of EbSe treatment by ESI-
MS/MS. This was performed keeping in mind that Cys residues have been described in 
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the literature as the target of EbSe modification, either by formation of a selano-Cys bond 
between the enzyme and inhibitor or with the EbSe serving as a thiol oxidant.  
 Modifications of TbHK1 were scored using digested peptides from EbSe treated 
and untreated enzyme that were subjected to ESI-MS/MS (Supplemental Data set 1). 
Using this approach, species were identified with dioxidized (sulfone) and trioxidized 
(sulfonic acid) modified C103 in both untreated and treated samples. In contrast, 
dioxidized and trioxidized C327 and C369 modifications were identified only in the EbSe 
treated samples (Figure 2.2). Peptides bearing oxidized C327 and C369 were not 
observed in the untreated samples, suggesting that they were either not present in the 
untreated sample or that the modified peptides were present but simply not detected in the 
untreated samples. Lastly, EbSe-conjugated through a seleno-sulfide bond to TbHK1 was 
not detected in the treated samples.  
 
Figure 2.2 TbHK1 Cysteine Residues    
Two Cys residues on the large lobe of TbHK1 are modified in EbSe treated samples. The 
predicted distribution of TbHK1 Cys residues, based on modeling to the yeast structure, 
with the nine Cys residues and the catalytic base (D214) included to indicate the active 
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site (Chambers et al., 2008c). The * indicates the Cys found by ESI-MS/MS to be 
oxidized in both untreated and EbSe-treated TbHK1, while the ** indicates the two 
oxidized Cys residues observed only in peptides from treated samples.  
 
Mutagenesis of individual Cys residues in TbHK1.  
The observation that EbSe modified both C327 and C369 suggested that one or 
both were important for catalysis and/or EbSe inhibition. Further, it hinted at the 
possibility of generating EbSe-insensitive enzyme by alteration of the putative target 
residues. To explore the role of the nine TbHK1 Cys residues (Figure 2.2) in catalysis 
and inhibition, variants harboring Cys to Ala changes of the residues were generated.  
The consequences of these modifications on enzyme activity were varied. Three 
of the variants (C212A, C327A, and C386A) lacked detectable activity (Table 2.1), while 
three other variants (C369A, C401A, and C402A) had subtly reduced specific activities. 
The remaining two variants (C242A and C445A) had specific activities similar to the 
unaltered enzyme. EbSe and TCEP were then tested against the active variants. Both 
compounds were potent inhibitors of all of the active variants (including C369A), with no 
detectable difference in sensitivity compared to unmodified TbHK1 (Table 2.1).  
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Table 2.1. Specific Activity and Sensitivity to of TbHK1 Cys Variantsa 
Variant Specific Activity (mmolmin-1µg-1) EbSe IC50 (µM) TCEP IC50 (µM) 
WT 0.60 ± 0.03 0.35 ± 0.07 6.6 ± 0.4 
C103A NAb   
C103S 0.17 ± 0.00 <WTc  
C212A NDd   
C212S 0.23 ± 0.01 <WT  
C242A 1.1 ± 0.12 0.55 ± 0.02 4.1 ± 0.3 
C327A ND   
C327S ND   
C369A 0.24 ± 0.02 0.26 ± 0.02 7.5 ± 0.4 
C386A ND   
C386S ND   
C401A 0.17 ± 0.03 0.29 ± 0.04 10 ± 0.7 
C402A 0.23 ± 0.01 0.43 ± 0.11 7.2 ± 0.2 
C445A 0.79 ± 0.01 0.52 ± 0.05 5.4 ± 0.1 
aExperiments were performed in triplicate and standard deviation is indicated. 
bNA, protein not expressed. 
cInhibition was 100% using EbSe at a concentration that inhibited WT protein 50%. 
dNot determined, as activity was not detected 
 
In an effort to recover activity from the inactive Cys to Ala variants (C212A, 
C327A, and C386A), the three Cys residues were altered by mutation to a more 
conserved residue, Ser. The C212S variant had reduced yet detectable activity, while the 
other two yielded activity barely above the threshold of the variability in the assay. 
Notably, C212S remained sensitive to EbSe inhibition (Table 2.1).  
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Effects of Cys variants on oligomerization.  
To explore the impact of Cys residue alteration on the protein tertiary structure, 
native gels were used to resolve hexamer and monomer abundance, which were then 
characterized by silver staining and western blotting, respectively (Figure 2.3A) 
(Chambers et al., 2008b). Hexamer abundance was not altered in most of the variants 
with C386A and C445A having ~2-fold increases in oligomer abundance (Figure 2.3A). 
Two TbHK1 variants (C327A and C369A) had slightly reduced levels of monomer (as 
determined by probing with the anti-six His antibody), while C445A had a ~10-fold 
reduction in monomer abundance, suggesting this residue influences oligomerization.  
The proteins were also incubated with MPB and biotinylation of monomeric TbHK1 
scored in order to further assess the consequences of Cys mutation on structure. Protein 
was resolved by native gel electrophoresis (4%), with monomer transferred to 
nitrocellulose followed by western blotting with antisera to the six His tag used for 
affinity purification (to score relative protein concentration) or an anti-biotin antibody to 
determine the relative level of biotinylation.  
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Figure 2.3 Relative hexamer, monomer, and free Cys abundance for TbHK1 and 
variants. (A.) Relative hexamer and monomer abundance of TbHK1 and Cys variants. 
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Relative hexamer abundance (hatched bars) was determined by densitometry of 
appropriately sized bands visualized by silver staining of a 4% native gel followed by 
comparison to TbHK1 (lane 1). Relative monomer abundance (black bars) was 
determined by western blot analysis of the appropriate region of a 4% native gel using an 
anti-RGSH6 antibody and comparison to TbHK1. (B.) MPB modification of the monomer 
was determined by incubating variants with MPB (50 µM) for 30 min and monitoring the 
appropriate region of the gel by western blotting using an anti-biotin antibody. 
Experiments were performed in triplicate and standard deviation is indicated, with 
representative data included above each bar graph. 
 
Using MPB to characterize surface exposed Cys residues in the TbHK1 variants, 
seven of the eight variants were labeled similarly to WT protein (Figure 2.3B). However, 
C445A had an increased number of free Cys residues available for biotinylation by MPB 
per monomer as compared to TbHK1. This amino acid alteration may lead to an unstable 
monomer that, as a result of the modification, has many of its Cys residues exposed and 
available for MPB modification. Additionally, neither EbSe nor TCEP impact 
oligomerization of TbHK1 (data not shown). 
 
Oligomers of C445A are indistinguishable from TbHK1 by electron microscopy.  
To date, the oligomers of TbHK1 have been refractory to structural studies due to an 
inability to generate useful crystals. However, EM analysis of recombinant protein 
suggests that enzyme oligomers are globular and roughly symmetrical, with an average 
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diameter of 18.25 ± 0.19 nm (Figure 2.4). The C445A variant, which has slightly greater 
abundance of hexamer in the native gel analysis (Figure 2.3A), had a similar distribution 
of sizes (average diameter = 16.5 ± 2.8 nm), suggesting the mutation had relatively little 
impact on gross architecture. Notably, the overall structure of the hexamers suggests a 
ring-shaped tertiary structure. 
 
Figure 2.4  Negative stain TEM analysis of globular TbHK1 hexamers.  
Samples of WT TbHK1 (upper) and C445A variant TbHK1 (lower) were analyzed using 
a JEOL JEM 1200 EX transmission electron microscope after negative staining. Inset 
contains enlargement of four representative protein particles. Scale bar = 100 nm. 
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DISCUSSION 
 Currently there are a limited number of drugs available for the treatment of 
African trypanosomiasis. These agents have drawbacks – several are limited to treatment 
of infections before the parasite has crossed the blood-brain barrier, while others are 
active against one but not both human-infective subspecies of T. brucei. Target-based 
drug discovery offers the advantage of assessing drug/target interaction and allowing 
potential anticipation of possible resistance mechanisms. 
 TbHK1, which has been genetically and chemically validated as a suitable target 
for therapeutic development, has been the subject of several screening campaigns for 
small molecule inhibitors (Chambers et al., 2008a; Dodson et al., 2010; Sharlow et al., 
2010b). The small molecule EbSe, the sulfur derivative EbS, and several structural 
analogs of EbS were identified in these campaigns, suggesting that the compounds could 
prove useful for probing the enzymology of the protein. Further analysis revealed that 
both EbSe and EbS were mixed inhibitors of TbHK1 (with respect to ATP) and both 
were toxic to parasites (Sharlow et al., 2010c). While the potency against recombinant 
enzyme and parasites was different (with IC50 values of 0.05 ± 0.03 and 2.0 ± 0.5 for 
EbSe and EbS compared to EC50 values of 2.9 ± 0.28 and 0.030 ± 0.067 for the two 
compounds, respectively), both were able to reduce parasite G6-P levels after acute 
exposure, suggesting that at least one possible in vivo targets was TbHK1 (Sharlow et al., 
2010a; Sharlow et al., 2010b). Recently, trypanothione reductase has been identified as a 
second potential target (Lu et al., 2013). With both targets being essential to the parasite, 
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it is difficult to resolve which (if either) are responsible for the toxic action of the 
molecules.  
 EbSe had previously been characterized as a mimic of glutathione peroxidase, 
utilizing reduced glutathione to reduce hydrogen peroxide and lipid hydroperoxides. 
Additionally, EbSe has also been identified as a potent electrophile, facilitating inter- and 
intramolecular disulfide linkages (Sakurai et al., 2006). For example, EbSe was found to 
have reacted with up to 8 Cys residues of human IDO, causing a change in conformation 
that led to IDO inactivation (Terentis et al., 2010). Here, we have pursued a further 
dissection of the mode of action of TbHK1 inhibition by this group of compounds with a 
particular focus on covalent Cys modification. The results of these efforts suggest that the 
inhibitory activity of EbSe against TbHK1 is likely the result of thiol oxidation of C327.  
Initially, we found that TbHK1 inhibition by EbSe was not relieved by 
enzyme/inhibitor dilution, which supported the idea that the compound was indeed 
irreversibly modifying the enzyme. This was in stark contrast to inhibition of a HK from 
Plasmodium falciparum (PfHK), which we have recently characterized (Harris et al., 
2013). While EbSe and EbS were ~10-fold more potent inhibitors of PfHK, inhibition by 
both was completely relieved by dilution (Harris et al., 2013). 
While the dilution experiments suggested that EbSe was irreversibly modifying 
TbHK1, the finding that EbSe inhibition was not reversible on treatment with DTT 
supported the notion that the inhibition was not due to the canonical promiscuous seleno-
sulfide formation that has been observed previously with EbSe. This supposition was 
supported by the mass spectrometry analysis, which revealed oxidized Cys species 
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including sulfone and sulfonic acid functionality at C103, C327, and C369, with the latter 
two sites of oxidations detected only in the EbSe treated samples. Mutational analysis 
revealed that C327 is essential while C369 could be altered without notable consequence 
on either catalysis or EbSe sensitivity, suggesting that inhibition of TbHK1 is a 
consequence of oxidation of the former Cys. Lacking a solved structure for either 
monomeric or heteromeric TbHK1, it is difficult to resolve the reasons for the observed 
inhibition as both C327 and C369 are predicted (based on modeling) to be on the large 
lobe of the enzyme at some distance from the active site.  
EbSe has been described as a thiol oxidant in other studies (Schewe, 1995; 
Sakurai et al., 2006) suggesting a model for TbHK1 thiol oxidation (Figure 2.5). In the 
model, the Se atom of EbSe is attacked by the Cys SH followed by a proton transfer. The 
resultant S-Se conjugate is then hydrolyzed, with a subsequent proton transfer followed 
by deprotonation of the OH to yield the initial Cys sulfoxide. This functionality was not 
observed by MS/MS analysis, and is expected to undergo rapid in situ oxidation to the 
corresponding sulfone and sulfonic acids that were observed by MS. In principle, the 
initial conjugation with EbSe would be reversible prior to hydrolysis, accounting for the 
finding that promiscuous Cys oxidation was not observed. This mechanism would also 
potentially explain the reduced potency of EbS. EbS is structurally nearly identical to 
EbSe but the Se-bearing molecule would likely be a more potent oxidizing agent.  
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Figure 2.5 Potential Scheme for EbSe-based oxidation of Cys residues in TbHK1.  
 
 Despite its potentially promiscuous nature, EbSe is non-toxic to humans and is 
currently deployed in phase III clinical trials for treatment of ischemic stroke (Stroke 
Trials Registry Home Page, as of 08/16/2013) and was found to improve the outcome of 
patients suffering stroke (Yamaguchi et al., 1998). These studies and others that indicate 
that EbSe has antibacterial properties as a consequence of inhibition of bacterial 
thioredoxin reductases (Lu et al., 2012) suggest that the benzisoselenazol derivatives 
could prove useful for therapeutic development. 
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Abstract 
Hexokinase (HK) is the first enzyme in the glycolytic pathway and is essential to the 
survival of Trypanosoma brucei in the human host, where it relies on glycolysis 
exclusively for ATP production. A high throughput screen for TbHK1 inhibitors 
identified several potential scaffolds for further consideration. Several inhibitors 
developed from a benzamidobenzoic acid scaffold have demonstrated potent inhibition of 
rTbHK1 in vitro, leading to the development of a probe inhibitor (Probe, SID 99437306, 
IC50 = 976 nM). However, this compound lacked activity against parasites, perhaps due 
to poor cell permeability. Modifications to Probe to improve permeability have been 
explored, yielding compounds with improved anti-parasitic activity against bloodstream 
form parasites (LD50 = 1.88 µM). Mechanistic studies show that these inhibitors are not 
competitive inhibitors, and presumably act through an allosteric binding site. Further, 
these inhibitors have little impact on a human cell line (IMR90) and on similar host 
enzymes, with >40 fold selectivity. Continued development of this scaffold could lead to 
a novel trypanocidal drug. 
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Introduction 
Trypanosoma brucei is the causative agent of African sleeping sickness in man 
and the wasting disease nagana in livestock. Together, theses two diseases cause 
thousands of deaths (Fevre et al. 2008) and cost billions of United States dollars in 
agricultural losses (Torr et al. 2005) to the under-developed region of sub-Saharan Africa. 
T. brucei is an extra-cellular parasite of the mammalian bloodstream and cerebrospinal 
fluid transmitted by tsetse fly vectors. The hemolymphatic stage presents fever and flu-
like symptoms, while the encephalitic stage can cause a variety of neurological malaises, 
including an inversion of circadian rhythms. Current treatment options are inadequate, as 
they require multiple transfusions, have toxic side effects, and many are only effective 
against one of the two subspecies and only a select few can treat the encephalitic stage of 
the disease. New therapeutics must be developed in order to further control this disease. 
When inhabiting the mammalian host, T. brucei represses mitochondrial function 
and relies completely on glycolysis for ATP production, making the enzymes of the 
glycolytic pathway potential drug targets. Genetic studies have validated the first enzyme 
in the pathway, hexokinase (HK), as a drug target (Chambers et al. 2008). Hexokinase 
catalyzes the transfer of the γ-phosphate of ATP to the 6 carbon of glucose, yielding 
glucose-6-phosphate (G6P) and ADP. T. brucei has two HKs, TbHK1 and TbHK2, which 
share 98% amino acid identity and both of which are essential to the bloodstream form 
(BSF) of the parasite. The enzymes share low identity with human hexokinases (30–
33%), suggesting they could be selectively targeted. Curiously, only TbHK1 is active 
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when produced from recombinant E. coli, making TbHK1 the primary subject of drug 
screens (Morris et al. 2006).  
Recently, a high throughput screening (HTS) campaign has identified novel 
TbHK1 inhibitors (Sharlow et al. 2010a). Several isobenzothiazolinones were identified 
in the screen, but this scaffold was found to act through a promiscuous cysteine 
interaction (Joice et al. 2013), and a structure-activity relationship (SAR) could not be 
established beyond the need for the cysteine reactive sulfur (Sharlow et al. 2010b). A 
singleton from the HTS, benzamidobenzoic acid, was more amenable to optimization, 
and after a generation of 104 analogues was produced, SID99437306 was identified with 
a 10-fold improvement in TbHK1 inhibition and named “Probe” (Figure 3.1 (Sharlow et 
al. 2010b)).  
The first generation of analogues showed that modifications to the amide linker 
were not tolerated, while the addition of bromine to the 5 carbon of the benzoic acid and 
substituting a branched lipophilic group for the 4-methoxy group on the parental 4-
methoxyphenyl moiety was found to enhance TbHK1 inhibition (Sharlow et al. 2010b). 
Probe represents the synergy of the latter two modifications (Figure 3.1). Probe was 
shown to be non-toxic to human cell lines (including A549, IMR-90, HeLa, and MDA-
MB-231 (Sharlow et al. 2010b)), have 40-fold selectivity for TbHK1 over the similar 
human enzyme glucokinase (hGK), and had minimal promiscuity in a screen against a 
panel of human kinases (Sharlow et al. 2010b). Additionally, Probe was a mixed inhibitor 
with respect to both substrates, suggesting it may bind an allosteric site unique to the 
parasite enzyme. Unfortunately, both the original benzamidobenzoic acid HTS hit and 
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Probe lacked significant activity against BSF parasites (LD50  >25 µM), necessitating 
further development of the scaffold.  
 
Figure 3.1 First Generation Development of the Benzamidabenzoic Acid Scaffold 
(A) Initial HTS hit, SID24797131. (B) Probe identified from first generation analogues, 
SID99437306. (C) Scaffold for second-generation analogues. Numbers indicate 
modification sites. 
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Materials and Methods 
Reagents 
Glucose-6-phosphate dehydrogenase, β-nicotinamide adenine dinucleotide 
(NAD+), adenosine triphosphate (ATP), and glucose were purchased from Sigma (St. 
Louis, MO). Dimethyl sulfoxide (DMSO) was purchased from Fisher Scientific 
(Pittsburgh, PA). Inhibitors were synthesized at the University of Kansas Specialized 
Chemistry Center (KUSCC). Isopropyl β-D-1-thiogalactopyranoside (IPTG) was 
purchased from EMD Millipore (Darmstadt, Germany).  
 
Recombinant Protein Production 
Recombinant TbHK1 and hGK was purified as described from a culture of E. coli 
M15(pREP) harboring  pQE30 (Qiagen, Valencia, CA) with TbHK1 or hGK cloned in 
frame with a 6-His tagging sequence (Morris et al., 2006). Briefly, a 10 mL bacterial 
culture was used to inoculate a 1 L culture which was grown to an OD600 of ~1 and then 
induced for 24 hr at room temperature with 500 mM IPTG and purified as described 
(Morris et al., 2006).  
 
Hexokinase Assays 
HK assays were performed in triplicate as described using a glucose-6-phosphate 
dehydrogenase (G6PDH) coupled reaction to measure enzyme activity in a 96 well plate 
(Misset and Opperdoes, 1984; Morris et al., 2006). In short, the coupled assay uses 
G6PDH to convert G6P generated by HK to 6-phosphogluconate with coincident 
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reduction of NADP to NADPH, which is monitored spectrophotometrically at 340 nm. 
For inhibition assays, inhibitors dissolved in DMSO are added to the reaction mix and 
incubated for 10 minutes prior to the addition of glucose to start the reaction. Inhibitors 
were counter-screened for inhibition of G6PDH. Data analysis was performed using 
KaleidaGraph 4.1 (Synergy Software, Reading, PA).  
 
Live/Dead Cell Assays 
To determine the impact of TbHK1 inhibitors on cell growth, 5×104 BSF parasites 
(cell line 90–13, a 427 strain) were added into 96-well clear-bottomed polystyrene plates 
in 200 µl HMI-9 (Hirumi and Hirumi 1989) supplemented with 10% fetal bovine serum 
and 10% Serum Plus (Sigma-Aldrich, St. Louis, MO) and grown in the presence of 
inhibitor (1 µl) or equivalently diluted DMSO for 3 days in 5% CO2 at 37°C. CellTiter 
Blue (Promega, Madison WI) was added (20 µl) and the plates incubated an additional 3 
hours under standard culture conditions. Fluorescence emission at 585 nm was then 
measured after excitation at 546 nm. DMSO solvent was maintained at or below 1%, with 
1% causing a 16% reduction in cell number at the end of the three-day assay. 
 
Results 
Second generation analogues are active against parasites. 
The second generation of inhibitors primarily explored different lipophilic groups 
on the phenyl group, a substitution that was well tolerated in first generation analogues 
(Figure 3.2; Table 3.1). It was believed that the lack of in vivo activity for Probe was due 
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to low cell permeability, and that the addition of a hydrophobic group(s) may improve 
permeability. A benzene ring was also added to the 5 carbon of the benzoic acid, a 
modification omitted in the previous generation. Studies with the previous generation 
showed that substituting the carboxylic acid for a tetrazole was acceptable, but not an 
improvement (Sharlow et al. 2010b), but this modification was made to the Probe 
scaffold to determine if there was any synergy or permeability improvement. Two of the 
second-generation compounds had trypanocidal activity, SID144241590 and 
SID144241595 (Table 3.1). SID144241590 had superior activity against TbHK1 in vitro 
and BSF parasites in vivo compared to SID144241595 and was named “Lead.” 
 
Table 3.1 Second Generation Inhibitors 
Structure PubChem SID 
TbHK1 
IC50 
(µM) 
BSF 
LD50 
(µM) 
% BSF 
Growth 
Inhibition 
(10 µM) 
% hGK 
Inhibition 
(10 µM) 
 
994373061 0.98 ± 0.067 >10 6.9 ± 3.0 <25 
 
144241588 4.8 ± 0.38 n.d.
2 64.1 ± 3.8 26.1  ± 2.7 
 
144241590 0.28 ± 0.002 
1.88 
± 
0.71 
95.4 ± 0.83 35.2  ± 8.3 
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Structure PubChem SID 
TbHK1 
IC50 
(µM) 
BSF 
LD50 
(µM) 
% BSF 
Growth 
Inhibition 
(10 µM) 
% hGK 
Inhibition 
(10 µM) 
 
144241591 5.2 ± 0.14 n.d.
 40.7 ± 17.1 92.1 ± 0.32 
 
144241592 4.0 ± 0.20 n.d. 68.7 ± 4.1 35.7  ± 3.6 
 
144241593 3.6 ± 0.12 n.d. 52.6 ± 9.5 54.2 ± 3.4 
 
144241594 7.1 ± 0.47 n.d. 54.9 ± 4.2 43.7  ± 3.8 
 
144241595 9.9 ± 0.64 
5.0 ± 
1.4 82.1 ± 2.3 55.5  ± 13.4 
1Probe included for comparison. 
2Not determined. 
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Figure 3.2 Lead with Modification Sites 
Lead was the most potent second-generation inhibitor and the scaffold for the third 
generation analogues. Numbers indicate modification sites for third generation inhibitors. 
 
Third generation compounds show limited improvement over Lead 
Third generation compounds mainly explored modifications to the benzene ring added in 
Lead to see if trypanocidal activity could be improved (Figure 3.2). In general, addition 
of electronegative groups was well-tolerated and produced some small improvements in 
LD50 values (Table 3.2). The addition of nonpolar groups reduced or ablated activity, and 
the replacement of the benzene ring with other lipophilic groups was also not tolerated.  
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Table 3.2 Third Generation Inhibitors 
Structure Pub Chem SID 
TbHK1 
IC50 
(µM) 
BSF 
LD50 
(µM) 
% BSF 
Growth 
Inhibition 
(10 µM) 
% hGK 
Inhibition 
(10 µM) 
 
162169424 12.1 ± 0.44 
3.5 ± 
0.63 99.7 ± 1.4 15.1 ± 3.2 
 
162169425 3.2 ± 0.38 n.d.
1 82.5 ± 7.1 22.2 ± 1.6 
 
162169426 >10 n.d. 81.4 ± 5.6 15.7 ± 3.0 
 
162169427 >10 n.d. 82.2 ± 13.9 17.6 ± 4.4 
 
162169428 >10 n.d. 76.7 ± 10.4 15.1 ± 2.6 
 
162169429 6.8 ± 0.16 n.d. 41.2 ± 18.3 14.1 ± 1.5 
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Structure Pub Chem SID 
TbHK1 
IC50 
(µM) 
BSF 
LD50 
(µM) 
% BSF 
Growth 
Inhibition 
(10 µM) 
% hGK 
Inhibition 
(10 µM) 
 
162169430 >10 n.d. 34.5 ± 13.5 13.9 ± 1.9 
 
162169431 7.4 ± 0.15 n.d. 0 0.7 ± 1.4 
 
162211070 >10 1.3± 0.1 93.6 ± 0.41 8.5 ± 3.4 
 
162211071 6.7 ± 0.38 n.d. 43.4 ± 16.8 0 ± 2.5 
 
162211072 3.5 ± 0.33 n.d. 51.0 ± 14.3 3.5 ± 7.1 
 
162211073 >10 1.0 ± 0.01 93.3 ± 3.4 14.3 ± 11.1 
 
162211074 >10 2.2 ± 0.80 90.7 ± 4.5 9.0 ± 3.6 
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Structure Pub Chem SID 
TbHK1 
IC50 
(µM) 
BSF 
LD50 
(µM) 
% BSF 
Growth 
Inhibition 
(10 µM) 
% hGK 
Inhibition 
(10 µM) 
 
162211075 0.73 ± 0.06 
1.5 ± 
0.31 92.2 ± 2.9 13.8 ± 1.9 
 
162211076 4.6 ± 0.32 
2.0 ± 
0.22 90.7 ± 0.93 18.8 ± 2.4 
 
162211077 >10 n.d. 57.7 ± 14.2 16.7 ± 1.2 
 
162211078 >10 1.8 ± 0.31 93.7 ± 2.6 16.1 ± 8.7 
 
162211079 3.1 ± 0.17 
16.8 
± 2.8 62.8 ± 14.9 22.1 ± 8.7 
 
162211080 >10 1.6 ± 0.37 94.0 ± 2.1 17.4 ± 8.0 
 
162211081 >10 n.d. 83.8 ± 4.0 24.2± 4.5 
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Structure Pub Chem SID 
TbHK1 
IC50 
(µM) 
BSF 
LD50 
(µM) 
% BSF 
Growth 
Inhibition 
(10 µM) 
% hGK 
Inhibition 
(10 µM) 
 
162211082 >10 n.d. 81.9 ± 4.6 32.2 ± 11.4 
 
162211083 1.3 ± 0.11 
5.2 ± 
0.88 92.8 ± 2.0 24.5 ± 2.5 
 
162211084 >10 1.1 ± 0.20 90.7 ± 1.8 30.9 ± 3.5 
 
162211085 1.2 ± 0.1 n.d. 28.4 ± 7.8 15.3 ± 1.8 
 
162211086 >10 n.d. 65.2 ± 0.23 16.6 ± 2.3 
 
163631669 4.0 ± 0.32 
1.2 ± 
0.05 82.8 ± 0.23 43.7 ± 4.1 
 
163631670 >10 6.0 ± 0.22 74.6 ± 1.0 27.8 ± 1.7 
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Structure Pub Chem SID 
TbHK1 
IC50 
(µM) 
BSF 
LD50 
(µM) 
% BSF 
Growth 
Inhibition 
(10 µM) 
% hGK 
Inhibition 
(10 µM) 
 
172112736 0.33 ± 0.03 n.d. 
68.51 ± 
2.09 
24.82 ± 
1.04 
 
172112737 1.28 ± 0.00 n.d. 
68.18 ± 
4.43 0 
 
172112738 0.76 ± 0.08 >10
2 91.74 ± 
2.25 
31.05 ± 
0.41 
 
172112739 0.60 ± 0.09 
3.27 
± 
0.53 
97.99 ± 
1.17 
26.56 ± 
0.40 
 
172112740 3.86 ± 0.12 
3.04 
± 
0.34 
89.77 ± 
1.08 
23.86 ± 
2.54 
 
172112741 >10 n.d. 54.19 ± 18.6 1.55 ± 0.70 
 
172112742 11.83 ± 1.09 n.d. 
77.77 ± 
2.95 
12.40 ± 
0.76 
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Structure Pub Chem SID 
TbHK1 
IC50 
(µM) 
BSF 
LD50 
(µM) 
% BSF 
Growth 
Inhibition 
(10 µM) 
% hGK 
Inhibition 
(10 µM) 
 
172112743 2.7 ± 0.28 
2.00 
± 
0.65 
84.36 ± 
0.32 8.99 ± 2.53 
 
172112744 2.7 ± 0.18 >10
2 97.5 ± 0.58 12.52 ± 4.79 
 
172112745 3.52 ± 0.339 n.d. 
81.65 ± 
1.46 
11.33 ± 
0.80 
 
172112747 3.00 ± 0.166 n.d. 
73.56 ± 
0.96 
15.79 ± 
2.97 
 
172112748 2.8 ± 0.197 n.d. 
22.52 ± 
12.33 8.72 ± 4.34 
 
172112749 >10 n.d. 16.37 ± 13.34 1.67 ± 3.18 
 
172112750 0.42 ± 0.02 n.d. 
58.98 ± 
8.17 
10.36 ± 
2.09 
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Structure Pub Chem SID 
TbHK1 
IC50 
(µM) 
BSF 
LD50 
(µM) 
% BSF 
Growth 
Inhibition 
(10 µM) 
% hGK 
Inhibition 
(10 µM) 
 
172112751 0.51 ± 0.06 n.d. 
73.71 ± 
3.65 3.13 ± 2.75 
 
172112752 0.47 ± 0.15 n.d. 69.15 ± 5.8 
12.50 ± 
1.31 
 
172112753 0.14 ± 0.01 n.d. 0 1.62 ± 0.51 
 
172112754 0.50 ± 0.05 n.d. 
57.00 ± 
7.07 6.04 ± 0.05 
 
172112755 >10 n.d. 31.30 ± 8.22 9.66 ± 2.26 
1Not determined 
2Value may be artificially high due to stability issues. 
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Discussion 
The second generation of analogues led to the identification of SID144241590, 
dubbed Lead, which was more potent than Probe both in vitro (IC50 = 0.28 µM) and in 
vivo (LD50 = 1.88 µM). Lead has a benzene ring attached at the 4 carbon of the benzoic 
acid (Figure 3.2). This may add a lipophilic element to the inhibitor that aides in 
membrane permeability, explaining the compound’s trypanocidal activity. Importantly, 
like Probe, Lead is non-toxic to IMR90 human cell lines and had limited promiscuity 
against a human kinase panel from Luceome Biotechnologies (Tucson, AZ). While Lead 
represented a significant improvement over Probe, the aim was a compound with an LD50 
under 1 µM, prompting the synthesis of third generation analogues, which explored the 
effect of modifications to the benzene ring. 
The third generation analogues lacked the leap in effectiveness seen with Lead. A 
handful of inhibitors showed slight LD50 improvement (SID162211070, SID162211073, 
SID162211075, SID162211078, SID162211080, SID162211084, and SID163631669), 
but none of these inhibitors LD50 values fell below 1 µM. Interestingly, all of these 
compounds modify the ring with electronegative groups (Table 3.2). The added bulk of 
the benzene ring may place it next to a basic residue in the binding pocket. Replacing the 
benzene with other rings or nonpolar groups completely ablated trypanocidal activity, 
despite some nitrogenous ring substitutions having very low IC50 values versus TbHK1 
(Table 3.2). It seems that the benzene and not merely a hydrophobic residue is needed for 
in vivo activity. The ring may facilitate binding with a transporter or other cofactor 
needed for entry to the glycosome, but an off target interaction cannot be ruled out. 
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Further work is needed to optimize the scaffold. The small improvements found in the 
third generation may be synergistic. Work is currently under way to solve the crystal 
structure of TbHK1. If successful, in silico docking studies with Lead and the structure 
could provide the clues to finding the binding site of these inhibitors, which would 
accelerate scaffold development. Overall, the Lead scaffold represents an exciting drug 
candidate, and necessitates further development.  
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ABSTRACT 
Parasites in the genus Plasmodium cause disease throughout the tropic and sub-tropical 
regions of the world. P. falciparum, one of the deadliest species of the parasite, relies on 
glycolysis for the generation of ATP while it inhabits the mammalian red blood cell. The 
first step in glycolysis is catalyzed by hexokinase (HK). While the 55.3 kDa P. 
falciparum HK (PfHK) shares several biochemical characters with mammalian HKs, 
including being inhibited by its products, it has limited amino acid identity (~26%) to the 
human HKs, suggesting that enzyme-specific therapeutics could be generated. To that 
end, interrogation of a selected small molecular library of HK inhibitors has identified a 
class of PfHK inhibitors, isobenzothiazolinones, some of which have IC50 values < 1 
mM. Inhibition was reversible by dilution but not by treatment with a reducing agent, 
suggesting that the basis for enzyme inactivation was not covalent association with the 
inhibitor. Last, six of these compounds and the related molecule ebselen inhibited P. 
falciparum growth in vitro (0.6 ≤ EC50 < 6.8 µM). These findings suggest that the 
chemotypes identified here could represent leads for future therapeutic development 
against P. falciparum.  
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INTRODUCTION 
Malaria is a global health concern, infecting over 200 million people a year. 
While four members of the genus Plasmodium commonly cause human malaria, P. 
falciparum infection is responsible for the most mortality annually. In addition to disease, 
the burden of malaria has global economic consequences, with an impact in developing 
nations that results from reduced worker productivity and markedly increased disability 
adjusted life years (DALYs), a measure of disease burden as a consequence of mortality 
and morbidity (World Health Organization, life cycle.who.int).  
The parasite has a complex life cycle, with the intra-erythrocytic stage being 
primarily responsible for pathology. This stage of Plasmodium lacks a complete TCA 
cycle and knockout and inhibitor studies of mitochondrial proteins have suggested that 
the mitochondrion is not a significant contributor to cellular ATP levels (Vaidya and 
Mather 2009; Olszewski et al. 2010). Notably, glucose consumption was found to be 
increased up to 100-fold in infected erythrocytes (Roth et al. 1982) and lactate levels 
were ~20-100 times higher than that from uninfected cells (Pfaller et al. 1982; Vander et 
al. 1990). These observations suggested that glycolysis was playing a key metabolic role 
for the parasite during the erythrocytic infection. Supporting this supposition, knockout 
studies revealed that the hexose transporter responsible for importing glucose was 
essential to the parasite, and inhibition of glycolysis with glucose analogs rapidly 
depleted parasite ATP ( van Shalkwyk et al. 2008; Slavic et al. 2010).  
The first committed step in glycolysis, catalyzed by hexokinase (HK), is the 
transfer of the γ-phosphoryl group from ATP to glucose. This reaction yields glucose-6-
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phosphate (G6P), a metabolite with multiple potential fates. First, it can be consumed in 
glycolysis. Alternatively, if funneled into the pentose phosphate pathway, the metabolite 
can serve in the generation of NADPH, which is a key component in the P. falciparum 
antioxidant defense and de novo nucleotide triphosphate biosynthesis pathways (Muller 
2004). 
The importance of this glycolysis to the malaria parasite and the observation that the 
single P. falciparum HK (PfHK) is predicted to share limited (24%) identity with human 
glucokinases (HsGlk, or HK IV), suggested that this enzyme could serve as a suitable 
target for therapeutics (Figure 4.1). Here, we describe the characterization of recombinant 
PfHK. Further, we have interrogated a small molecule library of known HK inhibitors to 
identify potential lead compounds that inhibit PfHK. Last, we have assessed the anti-
parasitic activity of these molecules against P. falciparum erythrocytic stage parasites and 
have found that several are potent anti-parasitic compounds. 
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Figure 4.1 Alignment of PfHK, TbHK1, and HsGlk 
Alignments of PfHK, Trypanosoma brucei HK1 (TbHK1, Tb427.10.2010), and human 
glucokinase (HsGlk, ABS31137.1). Sequences were aligned using CLUSTAL 0 (1.1.0). 
The * indicated completely conserved residues, while the colons (:) mark residues that 
share properties (>0.5 in Gonnet PAM250 matrix). Periods (.) indicated residues that fall 
at <0.5 on the Gonnet PAM250 matrix, indicating weak similarity. The boxed residue is 
the conserved catalytic base (Asp241 in PfHK).  
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MATERIALS AND METHODS 
Chemicals and Reagents 
Glucose-6-phosphate dehydrogenase, β-nicotinamide adenine dinucleotide 
(NAD+), adenosine triphosphate (ATP), and glucose were purchased from Sigma (St. 
Louis, MO). Dimethyl sulfoxide (DMSO) was purchased from Fisher Scientific 
(Pittsburgh, PA), while phosphoenol pyruvate (PEP), 2-phenyl-1,2-benzisoselenazol-
3(2H)-one (ebselen, Eb, PubChem SID 856002) and glucosamine were obtained from 
VWR International (West Chester, PA). Isobenzothiazolinones and benzamides in Table 
1 were obtained from the University of Kansas Specialized Chemistry Center (KUSCC).  
 
Recombinant Enzyme Purification and Assay Conditions 
The open reading frame PF3D7_0624000 (PlasmoDB) for the P. falciparum 
hexokinase (UniProt Q02155) was synthesized for codon optimization (Genescript, 
Piscataway, NJ), sequenced, and cloned into pQE30 (Qiagen, Valencia, CA). 
Recombinant PfHK, a ~55.3 kDa protein, was purified following a protocol developed 
for heterologous expression and purification of a HK from the African trypanosome. 
Briefly, a 10 mL bacterial culture of E. coli M15(pREP) harboring pQE30PfHK  with 
PfHK cloned in frame of a 6-His sequence (Morris et al. 2006) was used to inoculate a 1 
L culture which was grown to an OD600 of ~1 and then induced for 24 hr at room 
temperature with 500 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) and purified as 
described (Morris et al. 2006).  
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 HK assays were performed in triplicate as described using a coupled reaction to 
measure enzyme activity (Morris et al. 2006; Misset and Opperdoes 1984). In short, the 
coupled assay uses glucose-6-phosphate dehydrogenase (G6PDH) to convert glucose-6-
phosphate (G6P) generated by HK to 6-phosphogluconate with coincident reduction of 
NADP to NADPH, which is monitored spectrophotometrically at 340 nm. Kinetic 
analyses were performed using KaleidaGraph 4.1 (Synergy Software, Reading, PA).  
 
Hexokinase Inhibitor Library 
The collection of small molecules described here as a "selected small molecular 
library of HK inhibitors" was originally developed, identified, and characterized as part 
of a HTS campaign targeting hexokinase 1 (TbHK1) from the African trypanosome, 
Trypanosoma brucei. This screen was completed at the Pittsburgh Molecular Libraries 
Screening Center (PMLSC) using a 220,233 compound library that was made available 
as part of the NIH Molecular Libraries Roadmap Initiative. Analog development of lead 
compound scaffolds, including the isobenzothiazolinones and benzamidobenzoic acid 
derivatives used here, resulted from an "Extended Characterization Chemical Probe 
Development Plan" described in a Probe Report from the NIH Molecular Libraries 
Program (Sharlow et al. 2010b).  
 
P. falciparum viability assay  
Plasmodium falciparum 3D7 parasites were grown in O+ red blood cells at 1% 
hematocrit cultured in RPMI (plus L-glutamine, without NaHCO3) supplemented with 
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0.5% albumax, 0.37 mM hypoxanthine, 27 mM NaHCO3, 11 mM glucose, and 10 µg/ml 
gentamicin under 5% CO2, 5% O2, and 90% N2, 37o C. All assays were performed in 
triplicate in a total volume of 100 µL with DMSO-only incubations as a negative control. 
Parasitemia was determined following 72 hours of incubation by flow cytometry using 
acridine orange staining (1.5 µg/ml in PBS, 5 min, RT, FACSCanto II flow cytometer 
(BD Biosystems, Franklin Lakes, NJ).  
The dose response curves for compounds that caused > 50% growth inhibition at 
10 µM were pursued in a 96 well plate format using an asynchronous parasite culture. 
The starting parasitemia was 1%. IC50 values were determined by scoring parasite growth 
in three separate wells over a two-fold dilution series starting at 40 µM for each 
compound. Percent inhibition was calculated by comparison to parasites grown in the 
DMSO controls from each plate. Chloroquine was screened as a positive control starting 
at 1 µM. Averages of the triplicates were calculated and dose-response curves fitted and 
IC50 values determined using Prism (GraphPad Software). 
 
RESULTS 
While the importance of glycolysis to P. falciparum during mammalian infection 
has been established (Roth et al. 1982; Pfaller et al. 1982; Vander et al. 1990), the 
enzymes involved in the process have not been subject to in-depth characterization. This 
is likely due to the difficulty of classically purifying the parasite components from the 
complex milieu of the red blood cell contents (which includes many related host 
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activities). Additionally, the A-T rich nature of the Plasmodium genome has historically 
made production and analysis of recombinant enzymes difficult. 
Indeed, our initial forays into expression of PfHK in E. coli were unsuccessful 
despite repeated efforts using a battery of expression vectors and bacterial cell lines. 
Expression was finally achieved using a synthetic PfHK gene optimized with a codon 
bias that reflected those codons employed by E. coli. The recombinant enzyme, which 
was purified to ~95% homogeneity (as determined by Coomassie staining of an SDS-
PAGE gel), displayed Michaelis-Menten kinetics when substrate levels were increased 
(Figure 4.2A), and had an apparent Km values for glucose and ATP (0.62 ± 0.06 and 0.66 
± 0.08 mM, respectively) similar to those from yeast Hxk and T. brucei TbHK1 (Table 
4.1, (Morris et al. 2006)). The PfHK kcat value was 1.2 x 104 min-1, similar to that 
reported for a recently characterized T. brucei HK1 (2.9 x 104 min-1) (Morris et al. 2006). 
PfHK had an affinity for MgCl2 (apparent Km = 2.7 ± 0.4 mM) similar to that of TbHK1 
(apparent Km = 0.92 ± 0.21 mM). PfHK lacked detectable activity when CaCl2 or MnCl2 
was included in place of MgCl2 in the standard assay. The optimal pH for enzyme 
activity was found to be about pH 7.4, with enzyme activity reduced ~50% by a 1.2 pH 
unit change in either the basic or acidic direction (Figure 4.2B).  
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Figure 4.2 Effects of glucose concentration and pH on PfHK activity.  
(A) PfHK (200 ng) activity in response to increasing glucose concentration. (B) The pH 
profile of PfHK (200 ng) activity. Three different buffers with buffering capacity in the 
range of pH tested were used for the assay: PIPES (pH 6.2, 6.5, 7.0), TEA (pH7.4), and 
Tris (pH 8.0, 8.8). Reactions were performed in triplicate and standard deviation is 
indicated.
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Table 4.1 Kinetic characterization of rPFHK 
  Apparent Km (mM)  
 kcat (min-1) Glucose ATP 
rPFHK 1.2 x 104 0.62 ± 0.06 0.66 ± 0.08 
rTbHK12 2.9 x 104 0.09 ± 0.02 0.28 ± 0.1 
2Previoulsy published (Morris et al. 2006)  
 
The enzyme lacked detectable activity when alternative phosphoryl donors, 
including UTP, GTP, CTP, TTP, ITP, and PPi, were tested. Notably, ATP at 
concentrations greater than 3.5 mM was inhibitory to the reaction (data not shown). 
Products also inhibited the enzyme, with inclusion of ADP (10 mM) in the reaction 
inhibiting the enzyme ~94% (Figure 4.3). PPi was also inhibitory, while AMP only 
modestly (~22%) inhibited PfHK at 10 mM. G6P, another product of PfHK, inhibited the 
enzyme ~80% at 10 mM.  
 
Figure 4.3 Effects of phosphoryl-bearing compounds on PfHK activity.  
PfHK (200 ng) activity was assessed in the presence of 5 mM ATP supplemented with 
ADP, PPi, or AMP (all at 5 mM). Assays were performed in triplicate as described in the 
Materials and Methods and standard deviation is indicated.  
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Identification of small molecule inhibitors of PfHK.   
The completion of a HTS for inhibitors of T. brucei hexokinase 1 (TbHK1), 
yielded several scaffolds that have since been further elaborated to resolve structure 
activity relationships against that enzyme (Sharlow et al. 2010a). We have taken 
advantage of the reagents and assays developed therein to interrogate this selected small 
molecule library of HK inhibitors for PfHK inhibitors. These compounds have been 
rigorously characterized. For example, they do not inhibit the coupled reporter enzyme, 
are typically poor inhibitors of human glucokinase, have variable activity against TbHK1, 
and are minimally toxic to a number of mammalian cell lines (including A549, IMR-90, 
HeLa, and MDA-MB-231 (Sharlow et al. 2010a).  
Of the 16 hits obtained from the HTS effort against TbHK1, two groups were 
pursued as scaffolds for analog development against TbHK1. Our interest in the first 
analog group, which was based on five representative isobenzothiazolinones found in the 
TbHK1 HTS, was particularly piqued because one analog, SID 92126115, had been 
previously identified in a screen performed by GlaxoSmithKline of more than two 
million compounds for molecules with anti-Plasmodium activity (http://life 
cycle.ebi.ac.uk/chemblntd, (Gamo et al. 2010)). SID 92126115, which inhibited parasite 
growth 97% at 2 mM, was a potent PfHK inhibitor (IC50 = 0.16 ± 0.04 mM, Table 4.2). 
Other isobenzothiazolinones lacking the halogen substituents (SID 85747718 and SID 
17387000) had slightly increased IC50 values, though substitution of the sulfur atom with 
a selenium atom (to yield SID 856002, ebselen, Eb), increased potency of inhibition, a 
trend similar to that seen when Eb inhibition of TbHK1 was compared to that seen with 
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SID 17387000. Interestingly, Eb and SID 17387000 inhibition were reversible by dilution 
(data not shown, and Figure 4.4), which is in contrast to the irreversible inhibition 
observed with TbHK1 (Harris et al., unpublished observation). The reducing reagent 
DTT was able to prevent, but not reverse, Eb inhibition of PfHK, likely as a consequence 
of the preventative DTT binding directly to Eb to block its interaction with the enzyme 
(Borges et al. 2005). Last, the presence of the sulfur or selenium atom was important for 
inhibition of the enzyme, as substitution with either a carbon or oxygen atom at that 
position (SID 87225568 and 85752767, respectively) ablated inhibition. 
 
Table 4.2 PfHK Sensitivity to TbHK1 inhibitors  
PubChem SID Structure PfHK  IC50 (µM) 
TbHK1 
IC50 (µM)1 
P. falciparum 
EC50 (µM) 
92126115 
 
0.16 ± 0.04 3.8 ± 0.40 0.62 ± 0.062 
85747718 
 
0.27 ± 0.01 1.1 ± 0.34 1.1 ± 0.39 
17387000 
 
0.23 ± 0.03 2.0 ± 0.50 5.2 ± 0.23 
856002 
(Ebselen)  
0.01 ± 0.00 0.05 ± 0.03 6.8 ± 1.25 
87225569 
 
3.1 ± 0.28 >25 4.4 ± 0.36 
160644636 
 
ND3 ND 1.8 ± 0.72 
87325999 
 
>10 >25 ND 
85742034 
 
>10 >25 5.1 ± 0.82 
Se
N
O
SeSR
O
HN
SH
F
N
H
O
Cl
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PubChem SID Structure PfHK  IC50 (µM) 
TbHK1 
IC50 (µM)1 
P. falciparum 
EC50 (µM) 
85786735 
 
>10 >25 ND 
87225568 
 
>10 >25 >10 
85752767 
 
>10 >25 >10 
93575727 
 
>10 9.3 ± 3.5  >10 
99437306 
 
>10 0.98 ± 0.07 >10 
1Previously published in (Sharlow et al. 2010a and B) 
2Identified in a GSK screen as inhibiting 3D7 P. falciparum growth 97% at 2 µM 
(http://life cycle.ebi.ac.uk/chemblntd, (Gamo et al. 2010)).  
3ND, not determined. 
  
Br
Cl
HO O
H
N
O
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Figure 4.4 Characterization of PfHK inhibition by SID 17387000.  
(A) Dilution after inhibition with SID 17387000 recovers enzyme activity. PfHK (200 
ng) was incubated with SID 17387000 (0.5 mM) or buffer (10 minutes, on ice) before 
addition of other assay components, resulting in a ~100-fold reduction in SID 17387000 
concentration. (B) Addition of the reducing agent DTT (100 mM) before, but not after, 
addition of SID 17387000 (0.5 µM) prevented PfHK inhibition. Standard deviation is 
indicated. 
We also explored inhibition of PfHK with members of a second scaffold 
identified in the TbHK1 HTS, based around the benzamidobenzoic acid identified in the 
screen (SID 93575727). Further development of this class of compounds has yielded 
improved inhibitors of TbHK1, including the probe ML205 (SID 99437306, Table 3.1) 
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(Sharlow et al. 2010b). However, against PfHK, representatives of this class were either 
poor inhibitors (ML205 was ~40% inhibitory at 10 mM) or lacked detectable activity 
against the enzyme.  
PfHK inhibitors are toxic to P. falciparum.  
Glycolysis is important to P. falciparum during the erythrocytic infection, 
suggesting that inhibitors of the enzyme could be promising lead compounds for 
therapeutic development. To explore this possibility, we grew cultured Plasmodium 
parasites in the presence of compound and monitored cell density after 72 hr. Both the 
isobenzothiazolinones and benzamidobenzoic acid-based compounds were tested in this 
assay, with EC50 values determined for those that inhibited cell growth >50% at 10 µM 
(Figure 4.5, and Table 4.2). Compounds from the isobenzothiazolinones group included 
two of the most potent anti-malarial compounds, SID 92126115 and SID 85747718. 
While all of the compounds that inhibited PfHK were toxic to parasites, one molecule 
(SID 85742034) was toxic to parasites while not inhibiting PfHK. With the exception of 
SID 87225569, the anti-parasitic compounds had EC50 values that were 4 to 680 fold 
higher than the PfHK IC50 values. This discrepancy could result from the inability of the 
molecules to reach their target as a consequence of limited RBC and/or parasite cell 
permeability or trafficking. The identified PfHK inhibitors have minimal impact on 
human cell lines with EC50 values >12.5 µM (Sharlow et al. 2010a), suggesting at least 
20-fold greater toxicity toward parasites for the most potent compound (Table 4.2).  
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Figure 4.5  Isobenzothiazolinones inhibited the growth of P. falciparum 3D7 
parasites in a dose dependent manner.  
A two-fold dilution series of compounds SID 92126115 and 17387000 were incubated 
with parasites and percent inhibition was calculated by comparison to parasites grown in 
the DMSO controls from each plate. Chloroquine was included as a positive control. 
Averages of experiments performed in triplicate were calculated and EC50 values 
determined using Prism (GraphPad Software), with standard deviation indicated. 
 
DISCUSSION 
The intra-erythrocytic malaria parasite requires extracellular glucose for survival, 
largely due to the significant consumption of the hexose as a consequence of ATP 
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generation by glycolysis. Inhibitors of this pathway have demonstrated potent anti-
malarial activity. These include small molecules that interfere with hexose transport 
(Saliba et al. 2004), as well as glucose analogs like 2-deoxyglucose (van Schalkwyk et al. 
2008; Udeinya and Van Dyke 1981). 
PfHK, the first enzyme in glycolysis, has heretofore been considered an 
interesting potential target but has not been exploited due to an inability to produce active 
recombinant protein for in vitro characterization (Olafsson et al. 1992). Using an E. coli 
codon optimized gene, we have for the first time generated active PfHK. Characterization 
of PfHK revealed it to share a number of features with other HKs, including the finding 
that the reaction products G6P and ADP were inhibitors of the enzyme, suggesting the 
Plasmodium protein may be regulated via the feedback mechanism described for 
vertebrate HKs (Easterby and Qadri 1982). This observation was somewhat surprising 
given that an HK from the related apicomplexan parasite Toxoplasma gondii  (which is 
44% identical to PfHK) is not sensitive to substrate inhibition (Saito et al. 2002). PfHK is 
also kinetically similar to other HKs, having glucose, ATP, and MgCl2 Km values similar 
to HKs from other systems, including T. brucei and H. sapiens. The PfHK Km value for 
glucose was similar to that described by Roth from activity associated with infected RBC 
lysates (620 µM and 431 µM, respectively) (Roth 1987). These values are ~5-fold higher 
than the Km reported from HK activity associated with uninfected RBC lysates, 
suggesting that the host enzyme should outcompete the parasite enzyme for glucose 
under limiting conditions. However, glucose transport in the intra-erythrocytic parasite is 
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highly efficient, with the concentration of substrate inside the parasite rapidly reaching 
levels higher than that found in the external medium (Saliba et al. 2004). 
The second PfHK substrate, ATP, is required for activity but can also be an 
inhibitor of the enzyme. PfHK has a Km value for ATP well below the intra-erythrocytic 
ATP concentration (~3 mM) and is inhibited at ATP levels approaching those found in 
the host cytoplasm. While we anticipate that PfHK utilizes a pool of ATP distinct from 
that found in the host cytoplasm, there could be conditions under which the parasite has 
generated sufficient ATP to satisfy its needs. To continue to synthesize ATP could be 
damaging to the host cell, either directly as a consequence of usurping host glucose, or by 
depletion of host purines required for ATP synthesis, as the parasite cannot synthesize 
purines and must salvage them from the host. The finding that ATP is a regulator of HK 
activity is not novel amongst HKs (Dodson et al. 2011), though its role in the malaria 
parasite remains unclear. 
Taking advantage of a pre-existing library of small molecules designed around 
two scaffolds known to inhibit a trypanosome HK, we searched for inhibitors of PfHK. 
The two enzymes share limited sequence identity (28%, Figure 3.1), but nevertheless we 
found that members of one of the two classes of analogues, the isobenzothiazolinones, 
were more potent against PfHK than TbHK1 (Table 3.2). Additionally, the 
isobenzothiazolinone analog Eb, was extremely potent against PfHK (IC50 = 0.01 ± 0.00). 
Eb can promiscuously modify cysteine residues, and this non-specific interaction is 
known to be the mechanism of its inhibition of some enzymes, such as human 
indoleamine 2,3-dioxygenase (Terentis et al. 2010). However, site directed mutagenesis 
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of TbHK1 cysteines, including the two conserved in PfHK (residues 273 and 398 in 
PfHK) did not alter TbHK1 sensitivity to Eb inhibition, indicating that either cysteine 
residues are not involved in Eb inhibition, or that multiple cysteines must be bound in 
order for inhibition to occur. Unlike the trypanosome enzyme, PfHK inhibition by Eb and 
the isobenzothiazolinone SID 17387000 was reversible by dilution, suggesting that the 
inhibitors interact with the two enzymes differently.  
Previous research has demonstrated that Eb is toxic to P. falciparum, with EC50 
values similar to those found in our study (14 µM and 6.8 µM, respectively) (Hunter et 
al. 1989). Eb may have polypharmacological impact on the parasite, given the likely 
reactivity of the selenium atom with cellular cysteines. However, it is non-toxic to 
humans and is currently in phase III clinical trials for the treatment of stroke survivors 
(Stroke Trials Registry Home Page, as of 02/27/2013), suggesting that the consequences 
of off-target effects in the human host may be tolerable.  
The isobenzothiazolinone SID 92126115 was previously identified in a screen 
performed by GlaxoSmithKline of more than two million compounds for molecules with 
anti-Plasmodium activity, inhibiting parasite growth 97% at 2 mM (Gamo et al. 2010). 
SID 92126115 was a potent PfHK inhibitor with an IC50 value of 0.16 ± 0.04 mM. 
Isobenzothiazolinone inhibitors of PfHK were also effective at inhibiting the growth of 
cultured parasites, with EC50s below 10 µM. The EC50 values were higher that IC50s 
found for PfHK, likely due to issues with cell permeability and off target interactions. 
With the exception of SID 85742034, compounds that did not inhibit PfHK did not kill 
parasites.  
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In conclusion, several observations support the value of PfHK as a therapeutic 
target. First, the single copy gene product shares limited (26%) identify with the human 
equivalent enzyme. Second, the enzyme is responsible for catalyzing the first reaction in 
two critical pathways, glycolysis and the PPP, and is likely indispensible for parasite 
viability. Last, inhibitors of the enzyme can inhibit parasite proliferation, as demonstrated 
here. Together, these findings suggest the value of further consideration of the 
isobenzothiazolinone scaffold, as well as identification of additional new chemotypes, as 
a potential lead in therapeutic development.  
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ABSTRACT 
The protozoan parasite Leishmania major is the causative agent of cutaneous 
leishmaniasis in North Africa, the Middle East, and Asia. Mannose metabolism is critical 
to macrophage infective stages of the parasite, with mannogen serving as the primary 
energy storage molecule while the surface glycocalyx of the parasite contains high 
mannose content. The glycolytic enzyme hexokinase contributes to mannose metabolism 
by catalyzing the phosphorylation of glucose to glucose-6-phosphate (which can be 
converted to mannose-6-phosphate) or by phosphorylating mannose directly, making it a 
potential drug target. Here we have expressed and purified recombinant L. major 
hexokinase 1 (LmHK1). The enzyme shares kinetic characteristics with previously 
characterized Trypanosoma brucei hexokinase 1 (TbHK1), and two classes of 
compounds identified as TbHK1 inhibitors were found to inhibit LmHK1. These data 
suggest that LmHK1 is a bonafide drug target, and that compounds with dual efficiency 
against T. brucei and Leishmania could be developed.  
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INTRODUCTION 
Leishmania major is a protozoan parasite distributed in Northern Africa, the 
Middle East and in areas of China and India and is the etiological agent responsible for 
the majority of cases of human cutaneous leishmaniasis. The life cycle of the parasite is 
complex, with distinct stages in both the sand fly vector and the mammalian host. 
Coincident with these stages are differences in the array of expressed surface 
glycoconjugates and metabolic strategies, with each process being specialized for life in 
its particular environment.  
Surface molecule biosynthesis and hexose metabolism are connected by a 
requirement for phosphorylated hexoses including glucose-6-phosphate and mannose-6-
phosphate (Glc6P and Man6P, respectively). These sugars have a number of potential 
fates, including being metabolized through glycolysis for ATP production, being directed 
to the pentose phosphate pathway for DNA and RNA precursors, or being used to 
generate sugar-nucleotides for glycoconjugate biosynthesis.  
Given the diverse set of pathways in which phosphorylated sugars participate, it is 
not surprising that hexose uptake and phosphorylation are important to the parasite. 
Glucose uptake, for example, is critical for promastigote stage infection of macrophages 
(Burchmore et al. 2003). Mannose metabolism is important for pathogenic promastigote 
and amastigote forms, likely due to its role in mannogen biosynthesis; mannogen makes 
up more than 80% of the carbohydrate in these life cycle stages, suggesting it is the 
primary energy reserve for the parasite. (Ralton et al. 2003; Sernee et al. 2006). Through 
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a salvage pathway, mannose is converted to Man6P for the biosynthesis of the sugar-
nucleotide GDP-Man needed for mannogen production (Turnock and Ferguson, 2007).  
Generation of phosphorylated hexoses from environmental sugars is largely the 
result of sugar kinases. The enzyme hexokinase (HK) is responsible for the transfer of the 
γ-phosphoryl group of a nucleoside triphosphate (typically ATP) onto the 6 position of 
hexoses (generally Glc). The genome of L. major harbors two nearly identical HKs, 
LmHK1 (LmjF.21.0240) and 2 (LmjF.21.0250), in tandem on chromosome 21. The two 
471 amino acid proteins are predicted to be >99% identical at the amino acid level with a 
single residue difference (residue 468 is an Ala or Val in LmHK1 and 2, respectively). 
Predicted HK1s from other Leishmania species are also highly conserved with the 
LmHKs, with identity ranging from 98% in L. infantum (LinJ.21.0300) and L. donovani 
(LdBPK_210300.1) to 89% in L. braziliensis (LbrM.21.0310). This is greater identity 
than LmHK1 shares with the previously characterized T. brucei HK1 (TbHK1, 61% 
identical) and P. falciparum HK (PfHK, 32% identical). The human HKs (1-4) share 
limited identity to LmHK1, with human HK 1 and 3 being 36% identical. In addition, the 
human HKs are predicted to be almost twice as large as LmHK1, being 917 and 923 
residues, respectively, as a consequence of the fusion of two HK domains into a single 
polypeptide. Human glucokinase (human HK 4) shares identity levels (32%) similar to 
those of the other human hexokinases but is more similarly sized to LmHK1, being 
composed of 465 amino acids. Here we show the results of characterization and 
inhibition studies of purified recombinant LdHK1 from E. coli, showing the enzyme’s 
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distinct allosteric regulation compared to human and T. brucei HKs, and potential as a 
drug target. 
 
MATERIALS AND METHODS 
Chemicals and Reagents 
Glucose-6-phosphate dehydrogenase, β-nicotinamide adenine dinucleotide 
(NAD+), adenosine triphosphate (ATP), and glucose were purchased from Sigma (St. 
Louis, MO). Dimethyl sulfoxide (DMSO) was purchased from Fisher Scientific 
(Pittsburgh, PA), while phosphoenol pyruvate (PEP), 2-phenyl-1,2-benzisoselenazol-
3(2H)-one (ebselen, Eb, PubChem SID 856002) and glucosamine were obtained from 
VWR International (West Chester, PA). Isobenzothiazolinones and benzamides in Table 
1 were obtained from the University of Kansas Specialized Chemistry Center (KUSCC). 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) was purchased from EMD Millipore 
(Darmstadt, Germany). 
 
Recombinant Enzyme Purification and Assay Conditions 
The open reading frame LmjF.21.0240 (TriTryp DB) for L. major hexokinase 1 
was amplified from genomic DNA, sequenced, and cloned into pQE30 (Qiagen, 
Valencia, CA). Recombinant LmHK1, a ~51.7 kDa protein, was purified following a 
protocol developed for heterologous expression and purification of a HK from the 
African trypanosome (Morris et al. 2006). Briefly, a 10 mL bacterial culture of E. coli 
M15 (pREP) harboring pQE30: LmHK1 with LmHK1 cloned in frame of an N-terminal 
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6-His sequence was used to inoculate a 1 L culture which was grown to an OD600 of ~1 
and then induced for 24 hr at room temperature with 500 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG). The bacteria were then harvested, resuspended in lysis 
buffer, and incubated with lysozyme (1mg/ml) and DNase (7.5 units/ml) prior to 
sonication. Soluble recombinant enzyme was then purified as previously described 
(Morris et al. 2006). The protein was purified to 99% homogeneity (as determined by 
Coomassie Blue staining of an SDS-PAGE gel). 
HK assays were performed in triplicate as described using a coupled reaction to 
measure enzyme activity (Morris et al. 2006; Misset and Opperdoes 1984). In short, the 
coupled assay uses glucose-6-phosphate dehydrogenase (G6PDH) to convert glucose-6-
phosphate (G6P) generated by HK to 6-phosphogluconate with coincident reduction of 
NADP to NADPH, which is monitored spectrophotometrically at 340 nm. Kinetic 
analyses were performed using Kaleida Graph 4.1 (Synergy Software, Reading, PA).  
 
RESULTS 
The recombinant enzyme had a high affinity for both substrates, with apparent Km 
values for glucose and ATP of 0.13 ± 0.01 and 0.16 ± 0.04 mM, respectively. These 
values are similar to those for yeast Hxk and T. brucei TbHK1 (Table 5.1). 
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Table 5.1:  Kinetic characterization of LmHK1a 
Protein Apparent Km (mM)a 
 Glucose ATP Mannose 
LmHK1 0.13 ± 0.01  0.16 ± 0.04 0.11 ± 0.02 
TbHK1b 0.09 ± 0.02 0.28 ± 0.1 0.03 ± 0.01 
Yeast HKb 0.18 ± 0.1 0.25 ± 0.04 NDd 
aHK assays were performed in triplicate and standard deviation is shown 
bData compiled from (Morris et al. 2006) for comparative purposes. 
dND, Not determined. 
 
Using glucose as a substrate, the LmHK1 kcat value was 3.6 x 104 min-1, similar to 
that reported for the previously characterized TbHK1 (2.9 x 104 min-1) (Morris et al. 
2006). Interestingly, the enzyme could utilize mannose as an alternative to glucose, with 
an apparent Km value indistinguishable from that of glucose (0.11 ± 0.02 mM), and a 
higher Kcat than glucose (5.4 x 104 min-1).  LmHK1 required a divalent cation, being most 
active with MgCl2 and having no detectable activity when MnCl2 or CaCl2 were 
substituted for MgCl2 in the standard assay. The enzyme functioned across a broad pH 
range, with values between 6.2 and 8.0 supporting at least 50% of the activity found at 
the optimal pH of ~7.4 (Fig. 5.1B). Basic pH above 8.0 was strongly inhibitory.  
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Figure 5.1 Effects of glucose concentration and pH on LmHK1 activity.  
(A) LmHK1 (~200 ng) activity in response to increasing glucose concentration. (B) The 
pH profile of LmHK1 activity. Three different buffers with buffering capacity in the 
range of pH tested were used for the assay: PIPES (pH 6.2, 6.5, 7.0), TEA (pH7.4), and 
Tris (pH 8.0, 8.8). Reactions were performed in triplicate and standard deviation is 
indicated. 
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In addition to ATP, LmHK1 could also use the purine nucleoside triphosphate 
GTP as a phosphoryl donor, though the enzyme affinity was lower for this substrate (with 
an apparent Km value for GTP of 2.13 ± 0.10 mM). The pyrimidine nucleoside 
triphosphates CTP and UTP also supported activity with apparent Km values of 3.74 ± 
0.59 and 1.07 ± 0.08 mM. TTP, but not ITP or PPi, was also a competent substrate 
(Figure 5.2A). While the broad spectrum of nucleoside triphosphates used as substrates 
differed from that used by the previously characterized TbHK1 (Morris et al. 2006), both 
enzymes were similarly inhibited by high concentrations of ATP (LmHK1 Ki value of 
9.78 ± 0.97 mM, Figure 5.2B). Additionally, both enzymes were inhibited by ADP and 
not by AMP, although LmHK1 ADP inhibition (84 ± 5.1% at 10 mM) was observed 
under pH conditions distinct from the acidic ones required for ADP inhibition of TbHK1 
(Dodson et al. 2011a). The other product, Glc6P, had minimal impact on LmHK1 activity 
inhibiting the enzyme 22 ± 5.1% at 10 mM.  
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Figure 5.2 Effects of phosphoryl-bearing compounds on LmHK1 activity.  
(A) LmHK1 activity with 5 mM of different phorsphoryl-donors. (B) High concentrations 
(>5 mM) of ATP inhibit LmHK1 activity. In the insert, LmHK1 activity was assessed in 
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the presence of 5 mM ATP supplemented with ADP, or AMP (all at 5 mM). Assays were 
performed in triplicate and standard deviation is indicated.  
 
Testing molecules found to inhibit T. brucei hexokinase 1 (TbHK1) (Sharlow et 
al. 2010a, Dodson et al. 2011b), several LmHK1 inhibitors with varied potency have 
been identified. These include modest inhibitors like the flavonoid quercetin (32.1 ± 
0.48% inhibition at 10 mM) and the indazole-3-carboxylic acid derivative lonidamine, an 
anti-cancer drug that targets tumor HKs (73.7 ± 5.2% inhibition at 10 mM). More potent 
inhibitors were found following interrogation of a panel of analogs based on scaffolds 
found to be inhibitors of TbHK1 by high throughput screening (HTS) efforts. Ebselen, 2-
phenyl-1,2-benzisoselenazol-3(2H)-one (Eb, PubChem SID 856002, Table 5.2), an 
inhibitor of both TbHK1 and the P. falciparum HK (PfHK, (Harris et al. 2013)), inhibited 
LmHK1 with  an IC50 value of 2.2 ± 0.2 µM, very similar to that of TbHK1 (IC50 value of 
0.97 ± 0.03 µM). Likewise, structurally related isobenzathiazolinone inhibitors of TbHK1 
(SID17387000, for example) were similarly potent against LmHK1 (100% inhibition at 
10 µM). We also explored inhibition of LmHK1 with members of a second scaffold, 
benzamidobenzoic acid (SID 93575727), which was also identified in the TbHK1 HTS. 
Further development of this class of compounds has yielded improved inhibitors of 
TbHK1, including the compound named “Probe” (SID99437306, Table 2) (Sharlow et al. 
2010b). These benzamidobenzoic acid derivatives were similarly inhibitory to both 
TbHK1 and LmHK1 with SID99437306, for example, yielding nearly identical IC50 
values for both enzymes (Table 2). Against PfHK, however, representatives of this class 
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were either poor inhibitors (Probe was ~40% inhibitory at 10 µM) or lacked detectable 
activity (Harris et al. 2013). 
 
Table 5.2 LmHK1 Sensitivity to TbHK1 inhibitors1  
PubChem 
SID Structure 
LmHK1 
IC50 
(µM) 
TbHK1 
IC50 2 
(µM) 
PfHK 
IC50 2 
(µM) 
L. 
amazonensis 
EC50 (µM) 
T. 
brucei 
EC50 2 
(µM) 
P. 
falciparum 
EC50 (µM) 
856002 
(Ebselen)  
2.2 ± 
0.23  
0.97 ± 
0.033 
0.01 
± 
0.00 
4.10 ± 0.40 2.9 ± 0.28 6.8 ± 1.25 
99437306 
(Probe) 
 
1.1 ± 
0.07 
0.98 ± 
0.07 >10 >10 >10 >10 
60210941 
 
1.7 ± 
0.11 
0.28 ± 
0.002 >10 13.60 ±0.50 
1.9 ± 
0.71 N.D.
4 
12-phenyl-1,2-benzisoselenazol-3(2H)-one (ebselen, Eb, PubChem SID 856002) was 
obtained from VWR International (West Chester, PA) while the benzamide was 
obtained from the University of Kansas Specialized Chemistry Center (KUSCC). 
2Previously published in (Sharlow et al. 2010a and B; Harris et al. 2013). 
3Value established using commercially available compound.  Previously published 
TbHK1 value, using synthetic compound purified from contaminants after synthesis 
was 0.05 ± 0.03 µM (Sharlow et al. 2010a). 
4Not Determined.  
Eb has been found to be both an inhibitor of HKs from a number of parasite 
species including TbHK1 and PfHK (Table 5.2). The compound is also a potent anti-
parasitic compound, with EC50 values of 2.9 ± 0.28 and 6.8 ± 1.25 µM against T. brucei 
BSF parasites and P. falciparum red blood cell stages, respectively (Sharlow et al. 2010a; 
Harris et al. 2013). Against L. major promastigotes, Eb was found to have an EC50 value 
of 4.1 ± 0.4 µM (Sharlow et al. 2010b), supporting the merit of assessing additional HK 
Se
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inhibitors as potential anti-Leishmania lead compounds. SID99437306, which lacks 
activity against the Plasmodium parasite, was also ineffective against Leishmania 
parasites (EC50 value >10). However the third generation benzamidobenzoic acid 
derivative, SID60210941, did have moderate activity against Leishmania parasites (EC50 
value = 13.6 ± 0.5 µM). Notably, members of both scaffolds, the isobenzathiazolinone 
and benzamidobenzoic acid derivatives, are minimally toxic to a number of mammalian 
cell lines (including A549, IMR-90, HeLa, and MDA-MB-231 (Sharlow et al. 2010a).  
 
DISCUSSION 
While glycolysis appears to be nonessential for the survival of Leishmania 
parasite, several lines of evidence suggest the glycolytic enzyme LmHK1 could be a 
viable drug target. Amino sugars are major carbon source for amastigotes (Naderer et al. 
2010), which LmHK1 can phosphorylate (0.33 ± 0.1 mmol/min at 20 mM glucosamine), 
and inhibition of another glycolytic enzyme, pyruvate kinase, is toxic to the parasite 
(Sandoval et al. 2008). Furthermore, the importance of mannose, which LmHK1 has a 
high affinity for (Km = 0.11 ± 0.02 mM), has been well documented for both energy 
storage as mannogen (Ralton et al. 2003; Sernee et al. 2006) and for producing the 
parasite’s glycoprotein coat (Spath et al. 2000; McConville et al. 2002; Sacks et al. 2000).  
The kinetics of LmHK1 lends credence to the idea that glucose is not the 
enzyme’s primary substrate. Like TbHK1, LmHK1 is insensitive to G6P, unlike TbHK1, 
LmHK1 is inhibited by ADP at physiological pH. Perhaps insensitivity to G6P and 
inhibition by ADP allow LmHK1 to readily phosphorylate mannose while not depleting 
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ATP. LmHK1’s ability to utilize other NTPs may also allow it to metabolize mannose 
without affecting cellular ATP.  
Thus it is not surprising that LmHK1 inhibitors are toxic to parasites (Table 5.2). 
While Eb and isobenzathiazolinones in general are promiscuous cysteine binders that 
could kill Leishmania parasites through off-target effects, the third generation 
benzamidobenzoic acid derivative SID60210941 has been selected for hexokinase 
inhibition and is not considered promiscuous. Previous work with TbHK1 has shown that 
the benzamidobenzoic acids are mixed inhibitors with respect to both glucose and ATP, 
suggesting an allosteric binding site (Sharlow et al. 2010b). The 61% amino acid identity 
and shared inhibition by benzamidobenzoic acids between LmHK1 and TbHK1 suggests 
a shared binding site. The ten-fold increase in EC50 for SID60210941 against Leishmania 
compared to T. brucei could be the result of differences between the binding site, uptake 
and metabolism of the compound, or compensatory activity by Leishmania’s glucokinase. 
It may be possible to identify subsets of the benzamidobenzoic acid derivative library that 
are selective for LmHK1. Future in vivo studies will be needed to elucidate the 
contribution of LmHK1 to parasite metabolism and verify LmHK1 as a drug target. 
Additional screening is also needed to identify more potent LmHK1 inhibitors.  
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ABSTRACT 
Trypanosoma brucei relies on glycolysis exclusively for ATP production when infecting 
the human host, housing most of the pathway in glycosomes, a kinetoplast specific 
organelle related to peroxisomes. Compartmentalization of glycolytic enzymes has been 
suggested to be a means to avoid unregulated ATP consumption by the first two kinases 
in glycolysis, hexokinase (TbHK) and phosphofructokinase (PFK). However, the 
unanticipated extra-glycosomal distribution of T. brucei HK2 (TbHK2) suggests 
alternative or additional functions for the protein, particularly when it is localized 
proximal to the flagellum (in bloodstream form parasites) or basal bodies (in insect stage 
parasites). TbHK2 is targeted to glycosomes via a N-terminal peroxisome targeting 
sequence (PTS2), which is recognized by the peroxin targeting and import machinery. 
The PTS2 consists of ~11 amino acids which have been found in other higher eukaryotes 
to be removed after delivery to peroxisomes. Here we have shown that a 25 amino acid 
sequence immediately downstream of the PTS2 (named N-terminal domain 25, NTD25) 
serves as a flagellar targeting sequence. Using a fluorescently-tagged reporter system, we 
have found that the N-terminal end of TbHK2 is proteolytically processed; suggesting 
that removal of the PTS2 through regulated cleavage may serve as a means by which the 
NTD25 signal becomes exposed. Further, mutagenesis of conserved amino acids in these 
two domains has revealed residues critical to TbHK2 processing and localization. 
Elucidation of this alternative localization pathway may facilitate the identification of 
new drug targets and further our understanding of the unique role of HKs in T. brucei and 
potentially other kinetoplastid parasites.  
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INTRODUCTION 
Trypanosomes that infect mammals, including the African and American 
trypanosomes (Trypanosoma brucei and T. cruzi) and some Leishmania spp., harbor 
organelles called glycosomes that compartmentalize a number of important metabolic 
processes, including most of glycolysis, for which the organelle is named. T. brucei, the 
causative agent of African sleeping sickness, is notable for its dependence on glycolysis, 
relying exclusively on the pathway in the mammalian blood to generate ATP.  
The compartmentalization of glycolytic enzymes in the glycosome has been 
suggested to be a means to avoid unwanted ATP consumption by the first two kinases in 
glycolysis, hexokinase (TbHK) and phosphofructokinase (PFK), as neither enzyme is 
regulated by feedback inhibition at physiological pH (Nwagwu and Opperdoes 1982). 
However, the unanticipated extra-glycosomal distribution of TbHK2 (Joice et al. 2013) 
suggests alternative or additional functions for the protein, particularly when it is 
localized proximal to the flagellum (in bloodstream form (BSF) parasites) or basal bodies 
(in insect stage (PF) parasites).  
Proteins destined for glycosomes frequently bear either N-terminal or C-terminal 
targeting sequences that are similar to those found on polypeptides targeted to 
peroxisomes in other systems. These sequences, peroxisome targeting sequence 2 (PTS2) 
and PTS1, are located on the N-terminus and C-terminus respectively. These signal 
peptides are recognized by targeting and import machinery (PEX proteins) that are 
largely conserved from yeast to man (Galland and Michels 2010). The PTS2 consists of 
 139 
~11 amino acids which has been found in plant and animals to be removed after targeting 
to peroxisomes (Flynn et al. 1998). In constrast, the PTS1 is rarely removed.  
Removal of the PTS2 has been attributed to the activity of a serine protease, 
DEG15 in plants (Schuhmann et al. 2008) and TYSND1 in mammals (Kurochkin et al. 
2007). Similar processing has not been described in lower eukaryotes, including the yeast 
S. cerevisiae (Flynn et al. 1998; Helm et al. 2007). Here, we describe the processing of 
the PTS2 of TbHK2 in the early-branching eukaryote T. brucei, finding that proteins 
destined for the glycosome can be targeted to an alternative destination as a consequence 
of removal of the PTS2. 
 
MATERIALS AND METHODS 
Reagents and Chemicals 
Antibodies to Arginine-Glycine-Serine (Histidine)6 (RGS (His)6) and GFP 
(GF28R, which detects GFP and variants including eYFP) were purchased from Qiagen 
(Valencia, CA) and Thermo Scientific Pierce (Rockford, IL), respectively. Antisera to T. 
brucei hexokinase (αTbHK, at 1:100,000) and T. brucei glycerol kinase (αGK, 
1:100,000) were the kind gifts of Dr. Paul Michels. For western blotting, primary 
antibodies were detected with appropriate secondary antibodies conjugated to horseradish 
peroxidase (Rockland Immunochemicals) and were visualized using the ECL Western 
Blotting System (Pierce). Restrict enzymes were purchased from Promega (Madison, 
WI). 
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Parasite growth and transformation 
  BSF parasites were cultured in HMI-9 medium (Hirumi and Hirumi 1989) 
containing 10% heat-inactivated fetal calf serum at 37°C under 5% CO2. PF 
trypanosomes were grown in SDM-79 medium (Brun and Shonenberge 1979) 
supplemented with 15% fetal calf serum at 28°C with 5% CO2. Cultures were always 
harvested prior to entering stationary phase, i.e., at densities lower than 2 x 106 cells/mL 
for BSFs or 2 x 107 cells/mL for procyclic cells, by centrifugation.  
To explore the subcellular localization of TbHK2 truncations and assess PTS2 
processing, constitutively expressed eYFP-tagged versions of the TbHK2 PTS2 (residues 
1-11), PTS2NTD25 (N-Terminal Domain 25, residues 1-36), or NTD25 (residues 12-36) 
were cloned into pXS6 or pXS2 expression vectors. These vectors drive transgene 
expression from the T. brucei rRNA promoter, typically yielding robust expression 
(Alexander et al., 2002). Constructs were linearized with restriction enzymes (MluI for 
pXS2 and NotI for pXS6) and transfected into BSF strain Lister 427 cells (4 x 107 cells) 
using the Amaxa Human T Cell Nucleofector Kit (Lonza, Basel, Switzerland) as 
described (Burkard et al., 2007). For PF transfections, restriction enzyme linearized 
constructs were introduced by electroporation as described (Wang et al., 2000). Variants 
were generated using the parental pXS2 or pXS6 PTS2NTD25eYFP constructs and a 
QuikChange II Site-Directed Mutagenesis Kit (Stratagene, LaJolla, CA). Mutagenesis 
primers were prepared according to the manufacturer’s directions with average size of  
~35-45 base pairs bearing a one to three nucleotide change from the native sequence. 
Generation of all variants was confirmed by sequencing.  
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Fluorescence microscopy and subcellular fractionation  
For live cell imaging, parasites were washed in PBS, immobilized in CyGel 
prepared according to manufacturer’s directions (Abcam, Cambridge MA), and applied to 
glass coverslips and visualized on a Zeiss Axiovert 200M using Axiovision software 
version 4.6.3 for image analysis. Immunofluorescence (IF) assays on fixed parasites was 
performed as described (Joice et al. 2013).  
Fractionation of BSF parasite cell compartments was performed using increasing 
concentrations of digitonin as described (Joice et al. 2013). Briefly, BSF parasites (108 
cells) were washed in ice-cold buffer (25 mM HEPES, pH 7.4, 250 mM sucrose and 1 
mM EDTA) and then resuspended in 0.25 mL of the same buffer. The cell suspension 
was divided into aliquots containing ~50 µg of protein and digitonin added (0.01, 0.05, 
0.10, 0.25, 0.50, 0.75, and 1.00 mg digitonin per mg of protein). Cells were incubated for 
4 min (RT) followed by centrifugation (12,000 × g for 2 min), with the supernatant 
(released fraction) assayed by western blotting. Untreated cells and those permeabilized 
by incubation in 0.5% Triton X-100 (total release, TR) were included.  
 
RESULTS 
Hexokinases from trypanosomes have conserved N-terminal ends.  
A comparison of the N-terminal sequences of HKs from members of the order 
Trypanosomatida, including African trypanosomes (T. brucei brucei, T. brucei 
gambiense), the American trypanosome (T. cruzi) and Leishmania spp. (including L. 
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major and L. infantum), revealed that first 36 residues are highly similar (Figure 6.1A). 
This similarity is not limited to trypanosomes that infect mammals, as Angomonas 
deanei, a parasite of insects, shared 41% identity and 64% conserved residues with 
TbHK2 for the first 36 residues. The PTS2 sequence at the N-terminal end of the 
polypeptides is similar to that found on many glycosome-resident proteins and not 
exclusive to the HKs, as T. brucei aldolase (TbALD) and others possess a similar 
sequence. However, the similarity of the HK sequences to the glycosome-targeted 
TbALD is limited to the first 11 residues. Beyond the PTS2 is a 25-residue domain (the 
NTD25) that is not found on HKs from other systems (including human, Plasmodium, or 
plant) and appears to be unique to the Trypanosomatida HKs 
 
The NTD25 harbors a flagellar targeting sequence.  
The PTS2 is a targeting sequence that drives fully-folded proteins to peroxisomes, 
organelles that share many features with glycosomes. The trypanosome PTS2 has been 
likewise found to traffic proteins to glycosomes (Blattner et al., 1995), but the dual 
localization of TbHK2 (Joice et al. 2013) to glycosomes and the flagellum suggested that 
perhaps the TbHK2 ORF harbored multiple targeting sequences. To assess the role of the 
PTS2NTD25 in protein localization, parasites were stably transformed with expression 
vectors harboring truncations and variants of the PTS2NTD25 fused to the N-terminus of 
eYFP. Fluorescence of these variants was then observed to determine the impact on 
localization. 
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Expression of eYFP without an N-terminal addition yielded cytoplasmic 
distribution, as has been previously described (Bauer et al. 2014). Addition of the TbHK 
PTS2 sequence targeted the eYFP to glycosomes in both BSF and PF parasites (Figure 
6.1B, left column). Fusion of the PTS2NTD25 onto the N-terminus of eYFP yielded a 
more complex localization pattern, with distribution in glycosomes and in the flagellum 
(Figure 6.1B, middle column). Expression of eYFP bearing only the NTD25 yielded 
expression that was limited to the flagellum in PFs. The phenotype in BSF parasites 
expressing the construct was more complex, with the fluorescence also detectable in the 
flagellum. Perhaps the more startling observation was that the majority of the cells 
expressing detectable fluorescence had a partially detached flagellum, suggesting the 
expression of the fusion protein was altering flagellar physiology (Figure 6.1B, right 
column).  
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Figure 6.1 Sequence and Localization of PTS2NTD25 
(A) Alignment of the PTS2 NTD25 from T. brucei with other kinetoplast HKs. The 
NTD25 region is conserved in other kinetoplast HKs, but not other glycosomal proteins, 
such as T. brucei aldolase (TbALD). Tbg = T. brucei gambiense, Tc = Trypansoma cruzi, 
Lm = Leishmania major, Lin = Leishmania infantium. (B) Localization of 
PTS2NTD25eYFP fusion constructs. Immunofluorescence analysis of localization and 
phenotypic consequence of expression of PTS2NTD25eYFP fusions in PF (top row, 
pXS2) and BSF (bottom row, from stably integrated pXS6).  
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The N-terminus of the TbHKs is altered by proteolysis.  
The unexpected finding that the NTD25 harbors a competent flagellar localization 
signal led us to explore the mechanism that may be behind extra-glycosomal localization 
of the TbHKs. To determine if the N-terminal end of the TbHKs is processed to remove 
the PTS2 signal and thereby allow function of the NTD25 signal, recombinant TbHK1 
epitope-tagged with a C-terminal RGS (His)6 (rTbHK1, which is 98% identical to 
TbHK2 and shares an identical PTS2NTD25 at the N-terminus) was incubated with BSF 
lysate followed by SDS-PAGE and western blotting for the RGS (His)6. Incubation with 
BSF lysate led to slightly altered mobility of the ~51 kDa protein, a difference that was 
absent following incubation with heat-denatured lysate (Figure 6.2A). The subtle change 
in mobility of the rTbHK1 suggested an N-terminal processing event. 
To further explore this processing event, BSF parasites expressing 
PTS2NTDeYFP were lysed and the lysate incubated with or without a protease inhibitor 
cocktail (Figure 6.2B). Probing the resulting proteins with an antibody to eYFP revealed 
that the full-length fusion protein (indicated as α) was processed to two species (β and 
γ) with the more subtle processing step to β altering the mobility of the protein by ~ 1 
kDa while γ appeared to be ~4 kDa less than α. During the course of incubation, α was 
lost with the coincident accumulation of β and γ. In PF cells, a similar pattern of products 
was generated (not shown). The processing event impacted the N-terminal end, as the 
signal from α was lost over time when the sample was probed with anti-sera reactive to 
TbHK PTS2NTD25 (Figure 6.2B, lower row). While it remains unresolved if β is an 
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intermediate to γ formation, neither species maintains sufficient antigenic similarity to the 
TbHK PTS2NTD25 epitope to be detected.  
 
Figure 6.2 Processing of TbHK1 and PTS2NTD25eYFP 
(A) Western blot with RGS (His)6 antibody shows a reduction in the size of rTbHK1 
when incubated with 90-13 BSF trypansome lysate, but not when the lysate is boiled 
prior to mixing.  Possible mechanism behind the western blot results on the right. (B) 
Time course shows processing of the PTS2NTD25eYFP construct. Cell lysates of T. 
brucei expressing PTS2NTD25eYFP were incubated at 370C for 0, 1, or 3 hours in the 
presence or absence of protease inhibitor cocktail (PIC). New, smaller bands appeared 
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when the lysates were probed with an antibody to eYFP (α-FP, top panel) while signal 
faded when the the lysates were probed with an antibody to the PTS2 (α-PTS2, bottom 
panel). (C) Cell lysates of T. brucei expressing PTSeYFP, PTS2NTD25eYFP, or 
NTD25eYFP were incubated at 370C for 1 hour in the presence or absence of PIC and 
probed with α-FP. 
 
Variants of the N-terminus can be processed but are toxic to T. brucei.  
PTS2NTD25 fusions bearing alterations introduced by point mutation were used 
to identify residues that are critical for function of the processing and targeting. Serine 13 
of the TbHKs is an alanine in the same position in the HKs from T. cruzi and Leishmania 
spp. Altering this residue to an alanine to yield the variant S13A had no impact on either 
processing or cellular distribution (Figure 6.3A and B, respectively). Mutation of the 
conserved arginine 23 to alanine (R23A) also had no effect on processing, but instead had 
a catastrophic impact on cell morphology in both BSF and PF cells (Figure 6.3B). In BSF 
parasites, expression of the R23A eYFP fusion led to failure to properly divide, with 
fluorescence largely distributed to foci in the cell. PF cells also had a flagellar defect, 
with multiple flagella emanating from individual cells.  
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Figure 6.3 Processing and Localization of PTS2NTD25eYFP Point Variants 
(A) Overview of site-directed mutagenesis of PTS2NTD25eYFP construct residues to 
alanine and their effects on processing and localization. + = behaves like wildtype, β = 
not processed beyond β form, C = cytoplasmic; defect in localization, FD = flagellar 
defect; multiple flagella and/or defective cell division. *flagellar defect only present in 
double variant N6/7A. (B) Cell lysates of T. brucei expressing PTS2NTD25eYFP point 
variants were incubated at 370C for 1 hour (unless otherwise indicated) and probed with 
α-FP. (C) Subcellular fractionation of 427 BSF expressing PTS2NTD25eYFP wild type 
and N7A fusions. Trypanosomes were incubated with increasing concentrations of 
digitonin and release of eYFP and glycerol kinase (GK, a glycosome resident protein) 
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monitored by western blots.  Total release (TR) corresponds to cells incubated with 0.5% 
Triton X-100 to permeabilize all membranes. (D) Immunofluorescence analysis of 
distribution and phenotypic consequence of expression of PTS2NTD25eYFP point 
variants in BSF 427s (from stably integrated pXS6). Scale bars are 5 µM. 
 
 Altering asparagine 7 to alanine blocked the production of γ, even after 6 hours of 
incubation in cellular lysate (Figure 6.3A). Interestingly, localization by microscopy was 
not detectably altered (not shown). However, digitonin subcellular fractionation 
suggested a difference in distribution of the N7A variant from the unaltered fusion 
protein (Figure 6.3C). The α (full length) species from both unaltered and N7A variant 
PTS2NTD25eYFP was released at concentrations of detergent required to liberate 
cytosolic components, not surprising given that biosynthesis likely occurs on cytoplasmic 
ribosomes. The β species from cell lines harboring the N7A and unaltered fusions also 
behaved similarly, being released upon addition of sufficient digitonin to release 
glycosomal contents including the glycosome marker glycerol kinase (GK). This finding 
suggests that the β species may be a glycosome-resident molecule or that the processing 
activity may be glycosome-associated and released only upon detergent addition. The 
main difference between the N7A and the unaltered eYFP fusion was the absence of the γ 
species in the N7A samples. Cells expressing the unaltered fusion released γ after 
solubilization with 0.5% TX-100 (total release, TR), suggesting the species may reside in 
a digitonin-insensitive compartment. Because the N7A variant does not yield γ, it was 
predictably absent from the total release fraction.  
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Altering the aspartate 18, which is completely conserved in the NTD25s, to 
alanine (D18A) disrupted processing by blocking the formation of γ, but had no impact 
on cell growth. Likewise, changing the conserved residue glutamic acid 20 to alanine 
(E20A) prevented accumulation of γ but again was tolerated without ill effect by the 
parasites.  
 
DISCUSSION 
Glycosomes share similarities with peroxisomes, including the protein import 
mechanisms required for the introduction of glycosome resident proteins to the matrix of 
the organelle. While proteolytic processing of the PTSs is well documented in higher 
eukaryotes (Kurochkin et al. 2007; Helm et al. 2007), our study is the first example of 
PTS2 processing in lower eukaryotes. Further, the NTD25 flagellar targeting sequence 
identified appears to be specific to kinetoplasts, making this flagellar targeting pathway a 
potential drug target, as mislocalization of TbHK is lethal to parasites (Bakker et al., 
2000; Haanstra et al., 2008). 
Both the PTS2 and NTD25 appear to be cleaved in this localization pathway, 
resulting the production of 3 forms, which have been labeled as α, β, and γ (Figure 6.4). 
Point variants of the PTS2NTD25eYFP construct support this theory and show potential 
binding and cleavage sites of proteases (Figure 6.3). The processing of α to β appears to 
be required to expose the binding site for the protease responsible for the β to γ cleavage. 
Mutation of the N7 residue prevents recognition by this enzyme, while variants further 
downstream (D18A, E20A) are proposed to impact processing because they are near the 
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cleavage site. The R23A variant is interesting because although it is processed and 
localized normally, expression of PTS2NTD25eYFP R23A appears to interfere with 
flagellar function in cell division, suggesting that arginine 23 has a critical role in 
TbHK’s flagellar function.  
 
Figure 6.4 Proposed Model of TbHK2 Processing 
The PTS2 directs TbHK2 to glycosomes via PEX proteins. Processing and export from 
the glycosome reveals the NTD25, which directs TbHK2 to the mitochondria/basal 
bodies in PFs and the flagellum in BSFs, where the NTD25 is removed. Question marks 
indicate the action of 2 proteases yet to be identified.  
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Another curiosity is the difference in NTD25eYFP localization between life cycle 
stages (Figure 6.1). More studies are needed to determine if these localizations represent 
distinct functions or if the flagellar activities of TbHK are not used in PFs and the basal 
bodies are a reserve location. The discovery of TbHK processing has revealed a novel 
pathway for study and an exciting new potential drug target. 
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The abbreviations used are: BSF, bloodstream form; eYFP, enhanced yellow fluorescent 
protein; GK, glycerol kinase; HK, hexokinase; IF, immunofluorescence; NTD25, N-
terminal domain 25 amino acids found downstream of the peroxisome targeting sequence 
2 in T. brucei hexokinases; PF, procyclic form; PTS2, peroxisome targeting sequence 
type 2; PTS2, peroxisome targeting sequence type 2; PTS2NTD25, peroxisome targeting 
sequence type 2 and N-terminal domain 25 amino acids from T. brucei hexokinases; 
TbHK1, T. brucei hexokinase 1;  TbHK2, T. brucei hexokinase 2;  Tet, tetracycline 
repressor gene;  vPBS, Voorheis’s modified PBS.  
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CHAPTER SEVEN 
SUMMARY 
 Protozoan parasites continue to be a problem in the developing world, affecting 
the most vulnerable populations with the least resources to respond. The treatments for 
these diseases are decades old, and many are losing their effectiveness in the wake of 
emerging resistance and many also have toxic side effects. Thus there is a dire need for 
new therapeutics. These parasites have evolved to be highly specialized to suit the 
environment of their human host. One common adaptation by parasites is the repression 
of mitochondrial activity and increased glycolytic flux to take advantage of the abundant 
glucose in the host. This makes parasite glycolytic enzymes attractive targets for drug 
development. Hexokinase is of particular interest, because it catalyzes the first step of 
glycolysis, typically a rate-limiting step, and because it is also connected to a number of 
other biosynthetic pathways. Consequently, the hexokinases of Trypanosoma brucei, 
Plasmodium falciparum, and Leishmania major have been investigated as drug targets. 
 
Trypanosoma brucei 
 T. brucei is an extracellular parasite of the mammalian bloodstream and 
cerebrospinal fluid, transmitted by the bite of tsetse flies in sub-Saharan Africa. Fatal if 
untreated, African trypanosomiasis causes 10,000 deaths a year, and current treatments 
are inadequate due to the need for multiple intravenous infusions, toxic side effects that 
kill 5% of patients, and growing resistance. T. brucei is dependent on glycolysis for ATP 
production in the mammalian host, and its two hexokinase enzymes (TbHK1&2) have 
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been validated as drug targets (Chambers et al. 2008). A recent high throughput screen 
(HTS) has identified small molecule inhibitors of TbHK1 (Sharlow et al. 2010a). Two 
hits from the screen have been pursued as scaffolds for drug development: 
isobenzothiazolinones and benzamidobenzoic acid. Additionally, new 
immunofluorescence studies have shown that TbHK2 has an alternative localization to 
the flagellum, challenging the previous dogma that TbHKs were found only in the 
parasite’s glycosomes, specialized peroxisomes that house most of the glycolytic 
enzymes.  
 
Ebselen Mechanism of Action 
The most potent TbHK1 inhibitor identified in the HTS was ebselen, and several 
similar isobenzothiazolinone compounds were also identified as inhibitors. These 
inhibitors were shown to be non-competitive with substrates and did not effect enzyme 
oligomerization. Ebselen is known to promiscuously bind cysteine residues. To determine 
if cysteine interaction was the means of TbHK1 inhibition, TbHK1 incubated with 
ebselen or empty vehicle was submitted for mass spectrometry, and site-directed 
mutagenesis was used to create alanine variants at TbHK1 cysteine residues. Mass 
spectrometry showed that cysteines C327 and C369 in TbHK1 treated with ebselen had 
been irreversibly oxidized, while the mutagenesis experiments showed that C327, but not 
C369, was essential for TbHK1 activity. It appears that ebselen and presumably other 
isobenzothiazolinone compounds inactivate TbHK1 by oxidizing C327. While non-toxic 
to humans and currently in clinical trials for stroke victims (Stroke Trials Registry Home 
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Page, as of 01/26/2015), the promiscuous nature of ebselen and the inability to establish a 
structure activity relationship for the isobenzothiazolinone scaffold make further drug 
development unlikely. 
 
Development of the Benzamidobenzoic Acid Scaffold 
The benzamidobenzoic acid scaffold has shown remarkable improvement with the 
first and second generations of compounds. The best TbHK1 inhibitor identified from the 
first generation of compounds, SID99437306 (dubbed “Probe”), was 10-fold more potent 
than the initial HTS hit (IC50 = 0.98 ± 0.07 µM). It was also non-toxic to human cell lines 
and 40-fold selective for TbHK1 over the equivalent human enzyme (Sharlow et al. 
2010b). However, Probe still had the initial HTS hit’s fatal flaw of being ineffective 
against parasites in culture. A lack of cell permeability was believed to be the cause of 
Probe’s inability to kill parasites. Subsequent efforts were aimed at modifying the 
scaffold with hydrophobic residues to improve permeability. The best compound 
identified in the second generation of compounds, SID60210941, or Lead, is both more 
effective against TbHK1 (IC50 = 0.28 ± 0.02 µM), and effective against parasites in 
culture (LD50 = 1.88 ± 0.71 µM). The third generation of inhibitors, which explored 
additions to the benzene ring added in Lead, has led to only small improvements in IC50 
and LD50, but these changes may be additive. Further work is also needed to identify the 
mechanism of action of the benzamidobenzoic acids. While it is known that the 
compounds are mixed inhibitors with respect to glucose and ATP, the presumed allosteric 
binding site has not been identified. 
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Identification of TbHK’s Flagellar Targeting Sequence 
 The discovery that TbHK2 has extra-glycosomal localization to the flagellum 
prompted a search for a secondary targeting sequence within the protein. A 25 amino acid 
sequence in the N-terminus of TbHK2 (NTD25) immediately downstream of the 
peroxisome targeting sequence 2 (PTS2, which targets proteins to the glycosome) was 
found to have high conservation amongst only kinetoplastids. Immunofluorescence 
studies with PTS2, NTD25, and PTS2NTD25 fusions to eYFP showed that NTD25 is 
indeed a flagellar targeting sequence. Western blots of T. brucei lysate with 
PTS2NTD25eYFP show that two distinct processing events occur that alter the mobility 
PTS2NTD25eYFP. Site-specific alterations to PTS2NTD25eYFP have identified 
important residues for processing. Attempts at elucidating the cleavage site by mass 
spectrometry have been frustrated by technical problems. Nevertheless, these studies 
have revealed a kinetoplastid-specific pathway for further study and as a potential drug 
target. More work is needed to determine the exact sites of processing and identify the 
other proteins involved.  
 
Leishmania major Hexokinase 1 
L. major is one of Leishmania species that causes cutaneous leishmaniasis in the 
Old World, and is related to the more deadly Leishmania species that cause visceral 
disease. Leishmania species are intracellular parasites of mammalian macrophages, 
transmitted by sand fly vectors. While Leishmania is not dependent on glycolysis like its 
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kinetoplastid relative T. brucei, mannose, another hexokinase substrate, is important for 
Leishmania virulence. Leishmania uses mannogen as its primary energy store (Ralton et 
al. 2003) and its glycoprotein coat also has high mannose content (Davis et al. 2004).  
To characterize L. major hexokinase 1 (LmHK1), the gene was cloned from L. 
major genomic DNA into an E. coli expression vector to produce recombinant LmHK1. 
Kinetic characterization showed that LmHK1 was distinct from both TbHK1 and human 
HKs. While LmHK1 is insensitive to inhibition by its product glucose-6-phosphate like 
TbHK1, ADP does inhibit the enzyme, suggesting that the “turbo explosion” hypothesis 
(Haanstra et al. 2008) may not apply to Leishmania. LmHK1 also has an affinity and 
efficiency for mannose (Km = 0.11 ± 0.02 mM, Kcat = 5.4 x 104 min-1) on par with 
glucose (Km = 0.13 ± 0.03 mM, Kcat = 3.6 x 104 min-1), supporting the idea that it may be 
vital due to a role in mannose metabolism. Known TbHK1 inhibitors also inhibited 
LmHK1, and parasites were sensitive to some benzamidobenzoic acid compounds (EC50 
= 13.6 ± 0.5 µM). These findings suggest that LmHK1 may be a viable drug target, but 
further work is needed to prove that LmHK1 is essential.  
 
Plasmodium falciparum Hexokinase 
 Malaria is the most deadly parasitic disease in the world (>1 million deaths per 
year), and is caused by five species in the genus Plasmodium that are spread by female 
Anopheles mosquitos. P. falciparum is the most virulent species and causes the majority 
of deaths. Plasmodium species are intracellular parasites of red blood cells, causing fever, 
anemia, and in severe cases renal and brain damage. Plasmodium has repressed 
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mitochondrial activity in the mammalian host, and relies on glycolysis for ATP, with 
infected erythrocytes having up to a 100 times more glycolytic activity (Roth et al. 1982). 
Infected erythrocytes also have up to a 72-fold increase in activity in the pentose 
phosphate pathway, which the parasites rely on for producing reducing equivalents and 
nucleotide precursors (Roth 1987). HK catalyzes the first step in both of these pathways, 
making it an excellent drug target.  
 Recombinant P. falciparum HK (PfHK) was produced from E. coli bearing an 
expression vector containing an E. coli codon-optimized version of PfHK. PfHK has 
kinetic properties typical of an HK, and unlike the kinetoplastid HKs, is subject to 
feedback inhibition by its products. PfHK is insensitive to the benzamidobenzoic acid 
compounds, suggesting that the compounds may interact with a kinetoplastid-specific 
feature. PfHK was 10-fold more sensitive to ebselen (IC50 =0.01 ± 0.00 µM) than TbHK1 
(IC50 = 0.05 ± 0.03 µM), and P. falciparum parasites were also sensitive to ebselen (EC50 
= 6.8 ± 1.25 µM). Despite the conservation of TbHK1 C327 (as C398) in PfHK, ebselen 
may act on PfHK via a different mechanism, as ebselen inhibition of PfHK, but not 
TbHK1, can be rescued by dilution.  
 The central role of hexokinase in Plasmodium metabolism and these early studies 
show that PfHK is a promising drug target - hexokinase inhibitors are toxic to parasites. 
A HTS campaign is currently being prepared to identify more PfHK inhibitors. The 
screen will identify PfHK-specific inhibitors (PfHK and TbHK1 share only 29% amino 
acid identity), which will serve as scaffolds for further drug development. Another 
priority will be in vivo studies of PfHK. While studies of parasite metabolism and related 
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protein ssuggest PfHK is essential, this needs to be genetically validated. This future 
work will confirm PfHK as a drug target and provide starting points for drug 
development. 
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